53,099 results on '"Breast Tumors"'
Search Results
2. Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy (FASCINATE-N)
- Author
-
Zhimin Shao, Professor
- Published
- 2024
3. Current Status of Contralateral Prophylactic Mastectomy: Investigating Structural Racial Disparity.
- Author
-
Vadlakonda, Amulya, Curry, Joanna, Gao, Zihan, Chervu, Nikhil, Ali, Konmal, Hanjoo Lee, Thompson, Carlie K., and Benharash, Peyman
- Subjects
- *
PREVENTIVE medicine , *HEALTH services accessibility , *PEARSON correlation (Statistics) , *AFRICAN Americans , *BREAST tumors , *MULTIPLE regression analysis , *PROBABILITY theory , *WHITE people , *RETROSPECTIVE studies , *CHI-squared test , *DESCRIPTIVE statistics , *RACE , *LONGITUDINAL method , *LOG-rank test , *KAPLAN-Meier estimator , *ODDS ratio , *MEDICAL records , *ACQUISITION of data , *MASTECTOMY , *HEALTH equity , *SURVIVAL analysis (Biometry) , *CONFIDENCE intervals , *PROPORTIONAL hazards models ,BREAST tumor prevention - Abstract
BACKGROUND: Contralateral prophylactic mastectomy (CPM) remains a personal decision, influenced by psychosocial factors, including cosmesis and peace of mind. Although use of CPM is disproportionately low among Black patients, the degree to which these disparities are driven by patient- vs hospital-level factors remains unknown. STUDY DESIGN: Patients undergoing mastectomy for nonmetastatic ductal or lobular breast cancer were tabulated using the National Cancer Database from 2004 to 2020. The primary endpoint was receipt of CPM. Multivariable logistic regression models were constructed with interaction terms between Black-serving hospital (BSH) status and patient race to evaluate associations with CPM. Cox proportional hazard models were used to evaluate long-term survival. RESULTS: Of 597,845 women studied, 70,911 (11.9%) were Black. After multivariable adjustment, Black race (adjusted odds ratio 0.65, 95% CI 0.64 to 0.67) and treatment at BSH (adjusted odds ratio 0.84, 95% CI 0.83 to 0.85) were independently linked to lower odds of CPM. Although predicted probability of CPM was universally lower at higher BSH, Black patients faced a steeper reduction compared with White patients. Receipt of CPM was linked to improved survival (hazard ratio [HR] 0.84, 95% CI 0.83 to 0.86), whereas Black race was associated with a greater HR of 10-year mortality (HR 1.14, 95% CI 1.12 to 1.17). CONCLUSIONS: Hospitals serving a greater proportion of Black patients are less likely to use CPM, suggestive of disparities in access to CPM at the institutional level. Further research and education are needed to characterize surgeon-specific and institutional practices in patient counseling and shared decision-making that shape disparities in access to CPM. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Implication of calcium supplementations in health and diseases with special focus on colorectal cancer.
- Author
-
Khan, Shahanavaj, Mosvi, S. Needa, Vohra, Saeed, and Poddar, Nitesh Kumar
- Subjects
- *
CALCIUM metabolism , *BONE physiology , *VITAMIN D metabolism , *HOMEOSTASIS , *HEALTH status indicators , *CALCIUM-binding proteins , *HYPERTENSION , *GUT microbiome , *BREAST tumors , *COLORECTAL cancer , *TUMOR markers , *DIETARY calcium , *CALCIUM , *COLON tumors , *MUSCULOSKELETAL system physiology , *TUMORS , *CARCINOGENESIS , *DIETARY supplements - Abstract
Calcium is a fundamental and integrative element and helps to ensure optimal health by regulating various physiological and pathological processes. While there is substantiated evidence confirming the beneficial effects of calcium in the treatment, management, and prevention of various health conditions, including cancer, conflicting studies are imperative to acknowledge the potential negative role of calcium supplementation. The studies on calcium supplementation showed that a specific dose can help in the maintenance of good human health, and in the control of different types of diseases, including cancer. Calcium alone and when combined with vitamin D, emerges as a promising therapeutic option for efficiently managing cancer growth, when used with chemotherapy. Combination therapy is considered a more effective approach for treating advanced types of colorectal cancer. Nevertheless, several challenges drastically influence the treatment of cancer, such as individual discrepancy, drug resistance, and stage of cancer, among others. Henceforth, novel preventive, reliable therapeutic modalities are essential to control and reduce the incidence and mortality of colorectal cancer (CRC). The calcium-sensing receptor (CaSR) plays a pivotal role in calcium homeostasis, metabolism, and regulation of oncogenesis. Numerous studies have underscored the potential of CaSR, a G protein-coupled receptor, as a potential biomarker and target for colorectal cancer prevention and treatment. The multifaceted involvement of CaSR in anti-inflammatory and anti-carcinogenic processes paves the way for its utilization in the diagnosis and management of colorectal cancer. The current review highlights the important role of supplemental calcium in overall health and disease, along with the exploration of intricate mechanisms of CaSR pathways in the management and prevention of colorectal cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. Prospective cohort study of unmet supportive care needs, post-traumatic growth, coping strategy and social supports among patients with breast cancer: The PenBCNeeds study.
- Author
-
Azman, Nizuwan, Leong Bin Abdullah, Mohammad Farris Iman, Musa, Kamarul Imran, Hassan, Norsuraya, and Mohd Shariff, Noorsuzana
- Subjects
- *
RESEARCH funding , *BREAST tumors , *QUESTIONNAIRES , *POSTTRAUMATIC growth , *PSYCHOLOGICAL adaptation , *LONGITUDINAL method , *MEDICAL needs assessment , *SOCIAL support , *CANCER patient psychology , *EARLY diagnosis , *DELAYED diagnosis , *TIME - Abstract
Purpose: While the unmet healthcare needs are still being improved upon, the wellbeing of cancer patients has increasingly become a prime concern in Malaysia. The objective of this study is to ascertain the trend of unmet supportive care needs, post-traumatic growth (P T G), coping strategies, and social supports among patients with breast cancer over the three time points of treatment: T1 at early diagnosis, T2 for three months after diagnosis, and T3 for six months after diagnosis. Methods: A total of 240 cancer patients participated in this prospective cohort study, with follow-up visits from October 2019 until July 2021. Data were collected using several instruments: Brief COP E, the Source of Social Support Scale (SSSS), the Post-Traumatic Growth Inventory - Short Form (P T GI-SF), and a Malay version of the 34-Item Shortform Supportive Care Need Survey (SCNS-SF34). Results: The results indicated a significant change from T1 to T3 for all domains of the unmet needs (p-value < 0.001), except for the sexual domain. A lower SCNS-SF34 score resulted from more unfavorable social support. The P T GI-SF results indicated a trend toward meeting the unmet needs, and a higher SCNS-SF-34 score predicted a considerably higher P T GI-SF score. Conclusions: Our study findings suggest that majority of the factors evaluated in terms of unmet needs among cancer patients have undergone considerable changes. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
6. Development of a common dyadic coping scale in couples facing breast cancer: the importance of open communication.
- Author
-
Liu, Wenjia, Lewis, Frances Marcus, Li, Min, and Kantrowitz-Gordon, Ira
- Subjects
- *
SELF-evaluation , *GOODNESS-of-fit tests , *SECONDARY analysis , *RESEARCH funding , *BREAST tumors , *SPOUSES , *QUESTIONNAIRES , *RESEARCH methodology evaluation , *COUPLES therapy , *PSYCHOLOGICAL adaptation , *DESCRIPTIVE statistics , *CANCER patients , *EXPERIMENTAL design , *COMMUNICATION , *RESEARCH methodology , *RESEARCH , *PSYCHOMETRICS , *QUALITY of life , *FACTOR analysis , *COMPARATIVE studies , *INTERPERSONAL relations , *WELL-being - Abstract
Objective: Couples' joint coping is important in managing the impact of breast cancer. However, measures assessing couples' communication as a way of coping are insufficient. This study aimed to generate a self-report valid and reliable measure of couples' coping with a particular focus on communication. Method: We used baseline data of 343 couple dyads who participated in a randomized clinical trial targeting marital communication. Women were diagnosed with early-stage breast cancer in the past eight months; couples were married or in an intimate relationship for at least six months, could read and write English, and lived within 100 miles of the study center. An expert panel selected items with conceptual fit from the Mutuality and Interpersonal Sensitivity Scale (MIS) that was originally designed to evaluate marital communication about breast cancer. Results: Exploratory and confirmatory factor analyses supported a 12-item measurement model with four factors: Keeping the communication open with each other about breast cancer (4 items), Sharing a positive outlook on breast cancer (2 items), Avoiding discussion of negative thoughts and feelings about breast cancer (3 items), and Spending sufficient time together talking about breast cancer (3 items). Reliability ranged from 0.76 to 0.87 for women and 0.70 to 0.83 for spouses. Conclusion: This new measure has potential application in clinical practice and future research to assess couple's joint coping efforts especially through communication. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. Investigating executive functioning and episodic future thinking in Iranian women with breast cancer.
- Author
-
Falahatpishe, Zahra, Moradi, Alireza, Parhoon, Hadi, Parhoon, Kamal, and Jobson, Laura
- Subjects
- *
CROSS-sectional method , *TASK performance , *EXECUTIVE function , *BREAST tumors , *PSYCHOLOGY of women , *IRANIANS , *FACTOR analysis , *CANCER fatigue , *THOUGHT & thinking , *COGNITION - Abstract
Background: This study examined executive functioning and episodic future thinking among Iranian women with breast cancer. Method: We recruited 40 healthy female community volunteers and 80 females with breast cancer (either currently undergoing chemotherapy n = 40 or not undergoing chemotherapy n = 40). Participants were assessed using cognitive tasks that assessed executive functioning and episodic future thinking and a measure of cancer-related fatigue. Results: Both cancer groups had poorer performance than controls on all measures of executive functioning and episodic future thinking. Those undergoing chemotherapy had poorer performance on all measures of executive functioning than those not undergoing chemotherapy. Cross-sectional mediation analyses revealed cancer-related fatigue had a significant mediator role between cancer group and executive functioning and episodic future thinking. Conclusion: Those with breast cancer, particularly those undergoing chemotherapy, may be experiencing cognitive difficulties. These cognitive concerns should be considered by health teams as addressing these impairments may assist in improving quality of life and treatment adherence. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
8. Breast Health Perceptions and Screening Behaviors Among Myanmar American Immigrant Women.
- Author
-
San-Rozano, May M.
- Subjects
- *
HEALTH literacy , *IMMIGRANTS , *CROSS-sectional method , *SCALE analysis (Psychology) , *HEALTH services accessibility , *HEALTH attitudes , *ACCULTURATION , *STATISTICAL hypothesis testing , *T-test (Statistics) , *EARLY detection of cancer , *SOCIOECONOMIC factors , *BREAST tumors , *STATISTICAL sampling , *QUESTIONNAIRES , *FISHER exact test , *LOGISTIC regression analysis , *PSYCHOLOGY of women , *QUANTITATIVE research , *CHI-squared test , *MULTIVARIATE analysis , *ODDS ratio , *HEALTH behavior , *RESEARCH methodology , *MAMMOGRAMS , *STATISTICS , *HEALTH promotion , *CONFIDENCE intervals , *DATA analysis software , *LENGTH of stay in hospitals , *PATIENTS' attitudes , *ADULTS - Abstract
OBJECTIVES: To understand and describe attitudes toward general health checkups, breast health knowledge, cultural beliefs, and health-promoting behaviors among Myanmar American immigrant women in the United States. SAMPLE & SETTING: 267 women participated in the study. 10 women were excluded because of missing data, so the total sample size was 257 participants. METHODS & VARIABLES: A descriptive, crosssectional survey design was used to describe and investigate breast health perceptions and behaviors. RESULTS: Nearly 75% of the study sample reported having negative attitudes toward general health checkups and were found to have less accurate breast health knowledge and more fatalistic views about breast cancer. Only 29% of older women adhered to mammogram recommendations. Younger women reported more barriers to mammograms, and older women reported fewer barriers to mammograms. IMPLICATIONS FOR NURSING: This study demonstrated the need for additional research focusing on unique perspectives when investigating breast health practices among Myanmar American immigrant women. The findings highlight the essential need to build a strong partnership with stakeholders to combat breast health disparities and address the complex nature of acculturation. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
9. The Effects of Music Intervention on Quality of Life, Anxiety, and Fatigue Among Patients With Breast Cancer: A Randomized Controlled Trial.
- Author
-
Ching-Hui Chuang and Chung-Hey Chen
- Subjects
- *
ACADEMIC medical centers , *BREAST tumors , *MUSIC therapy , *STATISTICAL sampling , *TREATMENT effectiveness , *ANXIETY , *RANDOMIZED controlled trials , *DESCRIPTIVE statistics , *CHI-squared test , *CONTROL groups , *PRE-tests & post-tests , *STATE-Trait Anxiety Inventory , *QUALITY of life , *INFERENTIAL statistics , *CANCER patient psychology , *CANCER fatigue , *COMPARATIVE studies , *PSYCHOLOGICAL tests , *DATA analysis software , *MASTECTOMY , *CANCER patient rehabilitation ,ANXIETY prevention - Abstract
OBJECTIVES: To determine the effects of music intervention on quality of life, anxiety, and fatigue among patients with breast cancer. SAMPLE & SETTING: 170 individuals from the general surgery unit of Kaohsiung Chang Gung Memorial Hospital in Taiwan. METHODS & VARIABLES: Individuals who had received a mastectomy were randomly assigned to a treatment group or control group. In the treatment group, participants received music intervention for an hour each week, totaling 12 hours during 12 consecutive weeks. The primary variable was quality of life, and secondary variables were anxiety and fatigue. RESULTS: Greater quality of life was seen in the treatment group at 12 weeks. In the treatment group, participants showed significant improvement in State-Trait Anxiety Inventory (trait), which was most significant at eight weeks. No statistically significant difference was observed in fatigue levels after 4, 8, and 12 weeks of music intervention. IMPLICATIONS FOR NURSING: Music intervention may improve anxiety and quality of life of patients with breast cancer. Music intervention could be established following mastectomy and continued throughout recovery. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
10. The prognostic potential of mammographic growth rate of invasive breast cancer in the Nijmegen breast cancer screening cohort.
- Author
-
Peters, Jim, van Dijck, Jos A.A.M., Elias, Sjoerd G., Otten, Johannes D.M., and Broeders, Mireille J.M.
- Subjects
- *
BREAST cancer prognosis , *BREAST tumor diagnosis , *CANCER invasiveness , *RESEARCH funding , *EARLY detection of cancer , *BREAST tumors , *DESCRIPTIVE statistics , *CANCER patients , *LONGITUDINAL method , *ODDS ratio , *MAMMOGRAMS , *COMPARATIVE studies , *CONFIDENCE intervals , *OVERALL survival , *REGRESSION analysis - Abstract
Objectives: Insight into the aggressiveness of potential breast cancers found in screening may optimize recall decisions. Specific growth rate (SGR), measured on mammograms, may provide valuable prognostic information. This study addresses the association of SGR with prognostic factors and overall survival in patients with invasive carcinoma of no special type (NST) from a screened population. Methods: In this historic cohort study, 293 women with NST were identified from all participants in the Nijmegen screening program (2003–2007). Information on clinicopathological factors was retrieved from patient files and follow-up on vital status through municipalities. On consecutive mammograms, tumor volumes were estimated. After comparing five growth functions, SGR was calculated using the best-fitting function. Regression and multivariable survival analyses described associations between SGR and prognostic factors as well as overall survival. Results: Each one standard deviation increase in SGR was associated with an increase in the Nottingham prognostic index by 0.34 [95% confidence interval (CI): 0.21–0.46]. Each one standard deviation increase in SGR increased the odds of a tumor with an unfavorable subtype (based on histologic grade and hormone receptors; odds ratio 2.14 [95% CI: 1.45–3.15]) and increased the odds of diagnosis as an interval cancer (versus screen-detected; odds ratio 1.57 [95% CI: 1.20–2.06]). After a median of 12.4 years of follow-up, 78 deaths occurred. SGR was not associated with overall survival (hazard ratio 1.12 [95% CI: 0.87–1.43]). Conclusions: SGR may indicate prognostically relevant differences in tumor aggressiveness if serial mammograms are available. A potential association with cause-specific survival could not be determined and is of interest for future research. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
11. Trends and Patterns of Top Ten Common Cancers in Eastern India from 2014 to 2021: A Retrospective Hospital-based Cancer Registry Data Update.
- Author
-
Raj, Shraddha, Sinha, Dinesh K., Madhawi, Richa, Devi, Seema, Kishor, Kunal, Singh, Rajesh K., and Prakash, Aman
- Subjects
- *
CANCER treatment , *GALLBLADDER tumors , *LIVER tumors , *RADIOTHERAPY , *STOMACH tumors , *HEMATOLOGIC malignancies , *SCIENTIFIC observation , *SEX distribution , *HEAD & neck cancer , *BREAST tumors , *OVARIAN tumors , *REPORTING of diseases , *TERTIARY care , *RETROSPECTIVE studies , *ONCOLOGY , *AGE distribution , *TREND analysis , *DESCRIPTIVE statistics , *COLORECTAL cancer , *LYMPHOMAS , *LUNG tumors , *TUMORS , *DATA analysis software , *SPECIALTY hospitals ,CERVIX uteri tumors - Abstract
Background: India is a vast and diverse country with existing variations in the frequency and distribution of cancers across its various parts. In regions lacking population-based cancer registries (PBCRs) in a vast country like India, hospital-based cancer registry (HBCR) data become an important source of information on the trends and patterns of a region. To determine the numerical trends of cases of the top ten cancer sites reporting to HBCR of a tertiary care cancer center in Bihar from 2014 to 2021. Materials and Methods: The details of all histopathologically confirmed cancer cases registered in the HBCR department of radiation oncology, State Cancer Institute, Indira Gandhi Institute of Medical Sciences, Patna, India between January 2014 and December 2021 were included in this retrospective observational study. All these cases were grouped site-wise and listed in descending order of the total number of cases reported in each group. Cross-tabulation with age and sex distribution was done. The frequency distribution of the top ten leading cancers for every consecutive calendar year was plotted in line diagrams for time trend analysis. Statistical Package for the Social Sciences (IBM SPSS Statistics for Windows, Version 20.0. Armonk, NY: IBM Corp.). was used for analysis. Annual percent change (APC) was determined for the number of cases of all ten cancer sites using joinpoint regression analysis (Joinpoint Regression Software, Version 4.0.4--May 2013; Statistical Methodology and Applications Branch, Surveillance Research Program of the US National Cancer Institute; Bethesda, MD, USA). Results: Out of 32,057 total cancer cases registered between Jan 2014 and Dec 2021, 21,848 patients (68.2%) cases constituted the top ten cancers. The top ten cancers among both sexes were cancer gallbladder (n = 4204, 13.1%), head and neck (n = 3395, 10.6%), breast (n = 3392, 10.6%), lung (n = 2069, 6.5%), cervix (n = 2039, 6.4%), hematolymphoid (n = 1930, 6.0%), liver (n = 1572, 4.9%), stomach (n = 1116, 3.5%), ovary (n = 1103, 3.4%), and colon-rectum (n = 1028, 3.2%). Except for cervical and hematolymphoid cancers, the rest all showed a rising trend over consecutive years. Conclusion: Cancer of the gallbladder continues to be among the most common cancers in the region. Focused research in all aspects of this deadly disease is needed. Strengthening of prevention and screening programs for common cancers and upliftment of the existing infrastructure for diagnosis and treatment of cancer in the region are necessitated. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
12. MYB expression by immunohistochemistry is highly specific and sensitive for detection of solid variant of adenoid cystic carcinoma of the breast among all triple‐negative breast cancers.
- Author
-
Batra, Harsh, Bose, Priya S C, Ding, Yang, Dai, Alan, Chen, Hui, Albarracin, Constance T, Sun, Hongxia, Sahin, Aysegul A, Yang, Fei, Wistuba, Ignacio I, and Raso, Maria G
- Subjects
- *
ADENOID cystic carcinoma , *PROTEIN overexpression , *BREAST tumors , *DUCTAL carcinoma , *BREAST cancer , *BREAST - Abstract
Background: Adenoid cystic carcinoma is a rare subtype of triple‐negative breast carcinoma. These low‐grade tumours, which are treated by simple mastectomy and have an excellent prognosis compared to other triple‐negative breast carcinomas. Solid‐variant adenoid cystic carcinomas have basaloid features and are difficult to distinguish morphologically from other triple‐negative breast cancers. Breast adenoid cystic carcinoma exhibits MYB protein overexpression, which can be detected by immunohistochemistry (IHC). Aim: We compared the IHC expression of MYB in solid‐variant adenoid cystic carcinoma with that in other triple‐negative breast cancers. Methods: We conducted IHC staining of 210 samples of triple‐negative breast cancers, including solid‐variant adenoid cystic carcinoma (n = 17), metaplastic breast carcinoma (n = 44), basaloid triple‐negative breast cancer (n = 21), and other triple‐negative invasive ductal carcinoma (n = 128). We classified nuclear staining of MYB as diffuse/strong (3+), focal moderate (2+), focal weak (1+), or none (0). Results: All 17 solid/basaloid adenoid cystic carcinoma cases exhibited 3+ MYB expression. Of the 21 solid/basaloid triple‐negative breast cancers, one (5%) had 2+ expression, seven (33%) 1+ expression, and 13 (62%) 0 expression. Of the 44 metaplastic carcinoma cases, 39 cases (89%) had no (0) staining, and the other five cases had focal weak (1+) or moderate (2+) staining. Among the 128 triple‐negative invasive ductal carcinoma cases, 92 cases (72%) had no (0) staining, 36 cases (28%) exhibited focal weak (1+) or moderate (2+) staining. Conclusions: Our study revealed diffuse/strong MYB staining (3+) only in solid/basaloid adenoid cystic carcinomas. Thus, we recommend routine MYB IHC staining in triple‐negative breast carcinoma with solid/basaloid morphology to improve diagnostic accuracy. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
13. Targeted communication and race: explicating perceived message relevance.
- Author
-
Jensen, Jakob D., Loewen, Sherrie, Berger, Julia, Upshaw, Sean J., Christy, Katheryn R., and Lillie, Helen M.
- Subjects
- *
SCALE analysis (Psychology) , *AFRICAN Americans , *DATA analysis , *CRONBACH'S alpha , *RESEARCH funding , *HYPERTENSION , *BREAST tumors , *SEX distribution , *WHITE people , *DESCRIPTIVE statistics , *AGE distribution , *ANALYSIS of covariance , *RACE , *MULTIRACIAL people , *PSYCHOLOGY , *PRE-tests & post-tests , *COMMUNICATION , *INTENTION , *CONCEPTUAL structures , *ANALYSIS of variance , *STATISTICS , *HEALTH promotion , *FACTOR analysis , *THEORY , *COMPARATIVE studies , *CONFIDENCE intervals , *COGNITION - Abstract
Objectives: Targeting is a communication strategy in which a message is designed to address a particular group. It has been postulated that targeting increases message relevance; however, researchers are still explicating relevance and its impact on downline cognitive processes (e.g. message quality, cognitive cost). The current study addresses both gaps by evaluating the impact of targeted materials for White and African American audiences. Design: Adult women (N = 266) aged 18-74 (Mage = 47.12, SD = 1.40) were recruited to participate in a 2 (targeting: multiracial, African American) × 2 (race: White participants, African American participants) × 2 (topic: Hypertension, Environmental Breast Cancer) message experiment. Results: Across both topics, African American participants in the African American condition had reduced cognitive costs, increased message clarity, and increased message relevance. An indirect serial mediation model was supported wherein the relationship between targeting and behavioral intention was mediated by perceived relevance and perceived message quality. Conclusion: Targeting enhances perceived message relevance which, in turn, impacts behavioral intentions via perceived message quality. This model is consistent with the postulates of relevance theory and informs both intervention design and evaluation. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
14. Feasibility and Safety of the "One-Week Breast Radiation Therapy" Program.
- Author
-
Ba, M.B., Giudici, F., Bellini, C., Auzac, G., Louvel, G., Bockel, S., Moukasse, Y., Chaffai, I., Berthelot, K., Vatonne, A., Conversano, A., Viansone, A., Larue, C., Deutsch, E., Michiels, S., Milewski, C., and Rivera, S.
- Subjects
- *
PATIENT safety , *AESTHETICS , *RADIOTHERAPY , *BREAST tumors , *EVALUATION of human services programs , *DESCRIPTIVE statistics , *LONGITUDINAL method , *RADIATION doses , *DATA analysis software - Abstract
FAST-Forward and UK-FAST-trials have demonstrated the safety and efficacy of five-fraction breast adjuvant radiation therapy (RT) and have become the standard of care for selected early breast cancer patients. In response to the additional burden caused by the COVID-19 pandemic, we implemented "One-Week Breast RT," an innovative program delivering five-fraction whole breast RT in a complete 5-day workflow. The primary objective of this study was to demonstrate the feasibility and safety of our program. The secondary objective was to evaluate cosmetic results. A total of 120 patients treated from February 2021 to March 2022, received whole breast RT without lymph node irradiation nor boost, with 26 Gy in five fractions over one week. Inverse planning with restricted optimization parameters offers systematic deep inspiration breath-hold aimed to provide treatment plans compliant with FAST-Forward recommendations. Toxicity and cosmetic evaluations were prospectively registered prior (pre-RT), at the end (end-RT), and 6 months after RT (6 months) based on Common Terminology Criteria for Adverse Events v. 4.03 and Harvard scale. With a median age of 70 years (interquartile range (IQR): 66–74) and a median follow-up of 6 months (IQR: 6.01–6.25), most patients (93.3%) completed their RT in one week from baseline to the end of the treatment consultation. The most common acute toxicities (at end-RT) were skin-related: radio-dermatitis (72%), induration (35%), hyperpigmentation (8%), and breast edema (16%). The rate of radio-dermatitis decreased from end-RT to 6 months (71.7% vs 5.4%, P< 0.001). No patient experienced grade ≥3 toxicity. At 6 months, cosmetic results were generally good or excellent (94.1%). This study confirms the feasibility and acute safety of the "One-Week Breast RT" in real life. Favorable toxicity profiles and good cosmetic outcomes are in line with FAST-Forward results. A prospective national cohort, aimed at decreasing treatment burden, maintaining safety, efficacy, and improving RT workflow efficiency with longer follow-up is ongoing. • The "One-Week Breast RT" program (1WB) was successfully implemented in clinic. • The 1WB offers same-day consultation, treatment planning and first fraction delivery. • The 1WB shows same-week complete radiation therapy workflow is feasible. • The 1WB integrates FAST-Forward regimen, AI based contouring and scripted dosimetry. • The 1WB compares favorably to FAST-Forward trial acute outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
15. Estimated Doses to the Heart, Lungs and Oesophagus and Risks From Typical UK Radiotherapy for Early Breast Cancer During 2015–2023.
- Author
-
Holt, F., Ivanova, A., Wang, Z., Darby, S., Duane, F., Ntentas, G., Oliveros, S., Lavery, B., Shah, K., Eichholz, A., Dodwell, D., and Taylor, C.
- Subjects
- *
HEART disease related mortality , *RISK assessment , *DOSE-response relationship (Radiation) , *BREAST tumors , *RADIATION injuries , *SMOKING , *HEART , *LUNGS , *META-analysis , *SYSTEMATIC reviews , *LUNG tumors , *RADIATION doses , *ESOPHAGUS , *DISEASE risk factors - Abstract
Breast cancer radiotherapy can increase the risks of heart disease, lung cancer and oesophageal cancer. At present, the best dosimetric predictors of these risks are mean doses to the whole heart, lungs and oesophagus, respectively. We aimed to estimate typical doses to these organs and resulting risks from UK breast cancer radiotherapy. A systematic review and meta-analysis was conducted of planned or delivered mean doses to the whole heart, lungs or oesophagus from UK breast cancer radiotherapy in studies published during 2015–2023. Average mean doses were summarised for combinations of laterality and clinical targets. Heart disease and lung cancer mortality risks were then estimated using established models. For whole heart, thirteen studies reported 2893 doses. Average mean doses were higher in left than in right-sided radiotherapy and increased with extent of clinical targets. For left-sided radiotherapy, average mean heart doses were: 2.0 Gy (range 1.2–8.0 Gy) breast/chest wall, 2.7 Gy (range 0.6–5.6 Gy) breast/chest wall with either axilla or supraclavicular nodes and 2.9 Gy (range 1.3–4.7 Gy) breast/chest wall with nodes including internal mammary. For right-sided radiotherapy, average mean heart doses were: 1.0 Gy (range 0.3–1.0 Gy) breast/chest wall and 1.2 Gy (range 1.0–1.4 Gy) breast/chest wall with either axilla or supraclavicular nodes. There were no whole heart dose estimates from right internal mammary radiotherapy. For whole lung, six studies reported 2230 doses. Average mean lung doses increased with extent of targets irradiated: 2.6 Gy (range 1.4–3.0 Gy) breast/chest wall, 3.0 Gy (range 0.9–5.1 Gy) breast/chest wall with either axilla or supraclavicular nodes and 7.1 Gy (range 6.7–10.0 Gy) breast/chest wall with nodes including internal mammary. For whole oesophagus, two studies reported 76 doses. Average mean oesophagus doses increased with extent of targets irradiated: 1.4 Gy (range 1.0–2.0 Gy) breast/chest wall with either axilla or supraclavicular nodes and 5.8 Gy (range 1.9–10.0 Gy) breast/chest wall with nodes including internal mammary. The typical doses to these organs may be combined with dose-response relationships to estimate radiation risks. Estimated 30-year absolute lung cancer mortality risks from modern UK breast cancer radiotherapy for patients irradiated when aged 50 years were 2–6% for long-term continuing smokers, and <1% for non-smokers. Estimated 30-year mortality risks for heart disease were <1%. • Average mean whole organ doses were ∼2 Gy for heart, 3 Gy lung, and 4 Gy oesophagus. • Organ doses increased with increasing targets irradiated. • Estimated absolute 30-year radiation heart disease mortality risks were 0.2%–0.7%. • Equivalent lung cancer risks were 0.2%–0.4% for non-smokers and 2.3%–6.2% for smokers. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
16. Nipple adenoma, a rare benign tumor in accessory breasts: A case report.
- Author
-
ALI, RAWA M., SALIH, ABDULWAHID M., PSHTIWAN, LANA R. A., QADIR, ABDULLAH A., BABA, HIWA O., ABDULLAH, ARI M., ALI, HALKAWT OMER, DHAHIR, HARDI M., MOHAMMED, REBAZ O., and KAKAMAD, FAHMI H.
- Subjects
- *
NIPPLE (Anatomy) , *BENIGN tumors , *ADENOMA , *BREAST , *BREAST tumors , *BREAST ultrasound , *SURGICAL excision - Abstract
Nipple adenoma, an uncommon benign tumor, typically appears between the fourth and fifth decades of life, occasionally manifesting in accessory breasts. The embryonic mammary ridges give rise to accessory breasts along the milk line, and the lack of involution results in supernumerary breasts, including accessory nipples. This study aims to report a case of adenoma originating from an accessory breast nipple. The present study describes the case of a 23-year-old female patient who presented with right axillary discomfort and swelling. A physical examination revealed a tender, non-inflamed lump. A breast ultrasonography revealed features compatible with an accessory nipple, confirmed by excisional biopsy revealing adenoma. Throughout the 4-month follow-up period, no signs of recurrence were observed. Although rare, accessory breast tissue can harbor neoplasms, with nipple adenoma posing a diagnostic challenge often confounded with Paget's disease. Histologically, nipple adenomas exhibit diverse patterns, emphasizing the importance of a precise diagnosis. Adenoma of the accessory nipples is a rare condition that necessitates proper clinical assessment. Surgical excision remains the standard, yielding favorable outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
17. Parotid Lipomas: Case Series and Literature Review – A Case Report.
- Author
-
Unar, Ambreen Abdullah, Akhtar, Soubia, Iftikhar, Haissan, Ikram, Mubasher, and Akhtar, Shabbir
- Subjects
RISK assessment ,CYTOLOGY ,LIPOMA ,RARE diseases ,BREAST tumors ,TREATMENT effectiveness ,MAGNETIC resonance imaging ,PAROTID gland tumors ,NEEDLE biopsy ,DISEASE complications - Abstract
Background: Lipomas are the most frequent neoplasm of mesenchymal origin in the head-and-neck region. Around 15% of lipomas are found in the head-and-neck region. The usual site where lipomas can be found in the head-and-neck region is in the posterior triangle of the neck but they can also be found in the anterior neck, infratemporal fossa, submandibular space, larynx, pharynx, and parotid gland. The incidence of parotid lipoma ranges from 0.6% to 4.4% of all parotid neoplasms. There are two histological variants, focal lipoma and diffuse infiltrating variant. We describe two cases of rare focal lipoma of the parotid gland, therefore, must be reported. As rare as it may appear, existing relevant literature suggest management to includes definitive radiological investigations such as magnetic resonance imaging (MRI) and complete removal of lipoma with or without a cuff of parotid tissue. Case Report: Two cases were identified with a parotid lipoma on final histology. Case 1 is a 57-year-old male with a history of painless left parotid swelling for 2 years, reported to be 5 cm × 4 cm size on ultrasound, therefore, underwent superficial parotidectomy. Case 2 is a 67-year-old male who presented with right parotid swelling for 15 years, reported on ultrasound to be 5 cm × 5 cm, and underwent excision of intraparotid tumor. He later went on to develop breast carcinoma. The facial nerve was intact of both patients. Conclusion: Parotid lipomas are rare entities that should be a differential for clinically soft parotid swellings. Management includes definitive radiological investigations such as MRI and complete removal of lipoma with or without a cuff of parotid tissue instead of regular ultrasound followed by fine-needle aspiration cytology. Although our cases were managed on the same regular outlines, but reporting these cases would suffice the potential role of MRI and computed tomography scan for parotid swelling as per existing literature. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
18. Palbociclib in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer: A Systematic Scoping Review of Real-World Evidence from Countries Outside of Western Regions that Are Underrepresented in Clinical Trials.
- Author
-
Rauthan, Amit, Jain, Ankita, Singh, Manmohan, and Sendur, Mehmet A. N.
- Subjects
MEDICAL information storage & retrieval systems ,PROTEIN kinases ,PATIENT safety ,RESEARCH funding ,DATA analysis ,BREAST tumors ,ANTINEOPLASTIC agents ,TREATMENT effectiveness ,METASTASIS ,SYSTEMATIC reviews ,MEDLINE ,DRUG efficacy ,LITERATURE reviews ,ONLINE information services ,PROGRESSION-free survival ,EVIDENCE-based medicine ,OVERALL survival ,PHARMACODYNAMICS ,CHEMICAL inhibitors - Abstract
Introduction: Limited awareness exists regarding real-world data (RWD) for palbociclib in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced/metastatic breast cancer in populations from certain countries outside of Western regions. Methods: A systematic scoping review was conducted using PubMed and Embase to evaluate RWD for palbociclib from countries outside of Western regions that are underrepresented in clinical trials. Search criteria were aligned with our research question for relevant English-language publications, without restrictions on publication date, followed by Phase 1 (title and abstract) and Phase 2 (full-text) screening of retrieved citations as per Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Data analyses of eligible studies were done separately for abstracts and full-text publications to enhance the precision and reliability of the results. Results: Database search yielded 1485 non-duplicate records, 46 qualified for inclusion, of which 47.8% were published as full text. The analysis of outcomes, based exclusively on full-text publications that collectively included 2048 patients treated with palbociclib, revealed the median progression-free survival (PFS) of 20.2–36.7 months, overall survival (OS) of 39.9 months (reported in one publication) and objective response rate (ORR) of 45.3–80.0% with first-line treatment. In ≥ second line, the median PFS, OS and ORR ranged from 7.0 to 24.2 months, 11 to 19.6 months, and 13.9% to 47.9%, respectively. The safety profile of palbociclib was similar to that reported in pivotal clinical studies, and no new safety concerns were identified. Conclusions: A comprehensive volume of evidence demonstrates that palbociclib's effectiveness and safety profile in real-world settings align with those observed in clinical trials, offering valuable insights for clinical decision-making in countries outside of Western regions underrepresented in clinical trials. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
19. Cost-effectiveness of Pembrolizumab in Combination with Chemotherapy as Neoadjuvant Treatment and Continued as a Single Agent Adjuvant Treatment for High-Risk Early-Stage Triple-Negative Breast Cancer in Hong Kong.
- Author
-
Kwong, Ava, Leung, Roland, Chan, Tsz Ching, Khandelwal, Anvi, Mishra, Kshama, and Huang, Min
- Subjects
THERAPEUTIC use of antineoplastic agents ,COST effectiveness ,RESEARCH funding ,PATIENT safety ,DRUG side effects ,BREAST tumors ,ANTINEOPLASTIC agents ,QUESTIONNAIRES ,DESCRIPTIVE statistics ,EVALUATION of medical care ,TREATMENT effectiveness ,ADJUVANT chemotherapy ,COMBINED modality therapy ,QUALITY of life ,PROGRESSION-free survival ,MEDICAL care costs ,OVERALL survival - Abstract
Introduction: The phase III randomized KEYNOTE-522 trial demonstrated that pembrolizumab in combination with chemotherapy as neoadjuvant treatment followed by adjuvant pembrolizumab (pembrolizumab + chemotherapy) provided significant improvements in event-free survival (EFS) and overall survival (OS) for patients with high-risk early-stage triple-negative breast cancer (eTNBC). The objective was to assess the cost-effectiveness of pembrolizumab + chemotherapy compared to neoadjuvant chemotherapy alone (chemotherapy) in patients with high-risk eTNBC from a Hong Kong third-party payer perspective. Methods: A multistate transition model with four health states (event-free), locoregional recurrence, distant metastases, and death) was developed to assess the lifetime medical costs and health outcomes (3% annual discount), along with incremental cost-effectiveness ratios (ICERs) using efficacy and safety data from the KEYNOTE-522 trial. The health state utilities were derived from KEYNOTE-522 Euro-QoL-five-dimension five-level questionnaire (EQ-5D-5L) data. Costs were expressed in 2022 Hong Kong dollars (HKD). Scenario and sensitivity analyses were performed to assess the robustness of results. Results: Over a 32-year time horizon, base case results showed that pembrolizumab + chemotherapy was associated with a 3.42 year longer EFS and expected gains of 3.05 life years (LYs) and 2.45 quality-adjusted life years (QALYs) compared to chemotherapy. The resultant ICERs were HKD 135,200 per QALY gained and HKD 108,463 per LY gained, which were lower than the World Health Organization (WHO) cost-effectiveness threshold of three times gross domestic product (GDP) per capita for Hong Kong of HKD 1,171,308 per QALY. The one-way sensitivity analyses (OWSA) and probabilistic sensitivity analysis (PSA) showed the results were robust across various inputs and alternative scenarios. Conclusion: On the basis of the analysis conducted for a 56-year-old cohort with high-risk eTNBC and assumptions in the model, pembrolizumab + chemotherapy represents a cost-effective proposition (as the ICER is approximately 35% of the GDP per capita in Hong Kong) for patients with high-risk eTNBC in Hong Kong. Plain Language Summary: The manuscript outlines the methods and results of a health economic model to estimate the cost-effectiveness of pembrolizumab + chemotherapy compared to neoadjuvant chemotherapy alone (chemotherapy) in patients with high-risk early-stage triple-negative breast cancer in the Hong Kong setting. The results of the manuscript show that the combination of pembrolizumab and chemotherapy provides an additional 3.05 life years and 2.45 quality-adjusted life years. Despite the potential drawbacks of employing gross domestic product (GDP) as a proxy for cost-effectiveness thresholds, the incremental cost-effectiveness ratio was less than three times GDP per capita in Hong Kong. Therefore, the new intervention was cost-effective. However, like any similar study, the results rely substantially on extrapolation of trial outcomes and thus sensitivity analysis has also been performed to handle the uncertainty associated with results. The one-way sensitivity analyses and probabilistic sensitivity analysis showed the results were robust. The manuscript provides economic evidence of the new intervention and provides new clinical insights. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
20. Cisplatin Monotherapy as a Treatment Option for Patients with HER-2 Negative Breast Cancer Experiencing Hepatic Visceral Crisis or Impending Visceral Crisis.
- Author
-
Püsküllüoğlu, Mirosława, Pieniążek, Małgorzata, Rudzińska, Agnieszka, Pietruszka, Agnieszka, Pacholczak-Madej, Renata, Grela-Wojewoda, Aleksandra, and Ziobro, Marek
- Subjects
BREAST cancer prognosis ,HYPERBILIRUBINEMIA ,CISPLATIN ,BREAST tumors ,LOGISTIC regression analysis ,TREATMENT effectiveness ,RETROSPECTIVE studies ,DESCRIPTIVE statistics ,CANCER patients ,LONGITUDINAL method ,CANCER chemotherapy ,ODDS ratio ,METASTASIS ,ONCOGENES ,DRUG efficacy ,MEDICAL records ,ACQUISITION of data ,STATISTICS ,CONFIDENCE intervals ,PROGRESSION-free survival ,EPIDERMAL growth factor receptors ,OVERALL survival - Abstract
Introduction: Hepatic visceral crisis (VC), characterized by a rapid total bilirubin increase with disease progression, poses a life-threatening risk in advanced breast cancer (ABC). International consensus guidelines define VC and touch on impending VC (IVC). Limited data exist on systemic treatments for hepatic VC/IVC. This study explores the safety and efficacy of cisplatin monotherapy in patients with Human Epidermal Growth Factor Receptor 2- negative breast cancer (BC) and hepatic IVC/VC. Methods: In this retrospective single-center cohort study data of patients treated with cisplatin monotherapy (60–80 mg/m
2 , every 3–4 weeks) between 2016 and 2023 at a reference Cancer Centre in Southern Poland were analyzed. Results: 33 female patients (24/33 hormonal-positive) with the mean age 53.84 years were included. Participants progressed on median 2 prior palliative systemic treatment lines. In 10/23 patients hepatic VC and in 23/33 IVC (rapid, symptomatic liver progression; extensive liver involvement; alanine or aspartate aminotransferase > 2 × normal limit; significant increases in lactate dehydrogenase, alkaline phosphatase, or gamma-glutamyl transferase) were identified. Median progression-free survival was 1.87 months and median overall survival 2.67 months. 33% of the patients presented stable disease or partial response. Eight patients experienced adverse events grade ≥ 3: in five the dose of cisplatin was reduced; two stopped the treatment. Conclusion: Due to the hepatotoxicity of BC-active drugs, specific recommendations for systemic treatment are scarce. Our study explored cisplatin's potential use, finding it to be a viable option in patients with performance status 0 or 1 experiencing hepatic IVC/VC, irrespective of liver function parameters and other factors. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
21. Deciphering the Mechanism of Action Cosmos caudatus Compounds Against Breast Neoplasm: A Combination of Pharmacological Networking and Molecular Docking Approach with Bibliometric Analysis.
- Author
-
Hendrarti, Wahyu, Umar, Abdul Halim, Syahruni, Reny, Rafi, Mohamad, and Kusuma, Wisnu Ananta
- Subjects
BREAST tumors ,MEDICINAL plants ,CANCER treatment ,PHARMACOLOGY ,CELLULAR signal transduction - Abstract
Cosmos caudatus is a widely used traditional medicinal plant in Indonesia for cancer treatment. However, the mechanism of action of plants in treating breast neoplasms remains unclear. Thus, the active ingredients of C. caudatus and possible molecular pathways against breast neoplasms were investigated using pharmacological networks. The active compounds were screened using Lipinski and ADME parameters. Targets for the compounds were obtained using SwissTargetPrediction. Target diseases were identified using the Therapeutic Target Database, whereas disease pathways were analyzed using the Kyoto Encyclopedia of Genes and Genomes. Network pharmacology was constructed using Cytoscape. Protein-protein interactions were constructed using STRING. Gene ontology and KEGG were analyzed using DAVID. Molecular docking confirmed that the compounds and targets exhibited the best interactions. The compounds, targets, and pathways with the highest degrees in the breast neoplasm network were eriodictyol, ABCC1, and signal transduction, respectively. EGFR is the key target of PPIs. GO enrichment in BP, MF, CC, and KEGG regulated NF-KB transcription factor activity, chromatin, transcription coactivator binding, and pathways in cancer, respectively. Molecular docking with the best score on interaction 5-O-methylvisammioside-SLC2A1 (PDB ID: 6THA) (-10.3 kcal mol-1). The compound 5-O-methylvisammioside may have pharmacological activity in breast cancer through signal transduction pathways. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
22. The viral origins of breast cancer.
- Author
-
Lawson, James S. and Glenn, Wendy K.
- Subjects
- *
BREAST tumors , *PAPILLOMAVIRUSES , *EPSTEIN-Barr virus , *RETROVIRUSES , *VIRUSES - Abstract
During the past two decades evidence has been developed that indicates a handful of viruses with known oncogenic capacity, have potential roles in breast cancer. These viruses are mouse mammary tumour virus (MMTV - the cause of breast cancer in mice), high-risk human papilloma viruses (HPV-the cause of cervical cancer), Epstein Barr virus (EBV-the cause of lymphomas and naso-pharyngeal cancer) and bovine leukemia virus (BLV - the cause of cancers in cattle). These viruses may act alone or in combination. Each of these viruses are significantly more prevalent in breast cancers than in normal and benign breast tissue controls. The odds ratios for the prevalence of these viruses in breast cancer compared to normal and benign breast controls, are based on case control studies - MMTV 13·40, HPV 5.56, EBV 4·43 and BLV 2·57. The odds ratios for MMTV are much greater compared to the other three viruses. The evidence for a causal role for mouse mammary tumour virus and high risk for cancer human papilloma viruses in human breast cancer is increasingly comprehensive. The evidence for Epstein Barr virus and bovine leukemia virus is more limited. Overall the evidence is substantial in support of a viral cause of breast cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
23. Dipeptide PA3264 derived from rare and endangered Squama Manis is a novel bioactive peptide for the treatment of triple-negative breast cancer.
- Author
-
Hou, Xiaorong, Bai, Zhaofang, Chen, Yuanyuan, Shi, Wei, Yang, Huijie, Li, Ruisheng, Zhan, Xiaoyan, Liu, Youping, Zhao, Xu, and Xiao, Xiaohe
- Subjects
- *
THERAPEUTIC use of antineoplastic agents , *COMPUTER-assisted molecular modeling , *NF-kappa B , *OLIGOPEPTIDES , *BREAST tumors , *APOPTOSIS , *PHYTOCHEMICALS , *ECOSYSTEMS , *IN vivo studies , *CELL motility , *CELL lines , *MAMMALS , *ANIMAL experimentation , *GENE expression profiling , *CELL survival - Abstract
Background: Squama Manis is a valuable traditional Chinese medicine with a long history of medicinal use in the treatment of breast-related diseases. However, owing to the excessive exploitation and utilization of the resources, Squama Manis has been included in the list of rare and endangered wild animals. The conservation of the resources of Squama Manis and continuing its clinical application has become an urgent problem, and the search for small-molecule substitutes for Squama Manis is an effective way to achieve this goal. Previous studies have identified PA3264 as a possible active ingredient in Squama Manis. In this study, we systematically investigated the pharmacological effects and mechanisms of PA3264 in the treatment of triple-negative breast cancer (TNBC), a representative breast-related disease. Methods: Cell viability and colony formation assays were performed after treatment with the target dipeptide PA3264 in vitro. Next, 4T1 orthotopic tumors and humanized PBMC-CDX mouse models were generated to examine the antitumor effect of PA3264 in vivo. Transcriptome sequencing and molecular docking experiments were performed to predict pathways to function. Western blotting and quantitative real-time PCR were used to validate the molecular mechanisms underlying the anticancer effects of PA3264. Results: PA3264 significantly inhibited cell viability and migration of breast cancer cells in vitro. Furthermore, PA3264 suppressed the tumor size and reduced the tumor weight in vivo. Finally, it was verified that PA3264 prevented the progression of breast cancer by inhibiting the PI3K/AKT/NF-κB pathway, causing cell cycle arrest, and promoting apoptosis. Conclusions: This study elucidated that PA3264 derived from rare and endangered Squama Manis was a novel bioactive peptide for treating triple-negative breast cancer from a scientific research perspective. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
24. Can a fast T2-Dixon sequence surpass the time obstacle of whole-body MRI in the evaluation of skeletal metastases?
- Author
-
Elmansy, Mostafa, Magdi, Noha, Elhawary, Mohammed A., and Sultan, Amina
- Subjects
KIDNEY tumors ,DIAGNOSTIC imaging ,STOMACH tumors ,NON-Hodgkin's lymphoma ,BONE marrow cancer ,BREAST tumors ,LARYNGEAL tumors ,OVARIAN tumors ,MAGNETIC resonance imaging ,PROSTATE tumors ,DESCRIPTIVE statistics ,DIAGNOSTIC errors ,BONE metastasis ,LONGITUDINAL method ,COLON tumors ,LUNG tumors ,DATA analysis software ,MEDICAL artifacts ,SENSITIVITY & specificity (Statistics) - Abstract
Background: Whole-body magnetic resonance imaging (WB-MRI) has shown its accuracy in the diagnosis of skeletal metastases in patients with known primary solid cancers. The standard protocol was a combination of T1 and short tau inversion recovery (STIR) sequences. Herein, this study was conducted to elucidate the role of the T2-Dixon sequence as a rapid alternative to the standard protocol with the assessment of its diagnostic accuracy and comparability to the established methodology. Methods: This prospective study included 30 patients with primary solid malignancies who underwent WB-MRI. The sequences obtained were T1WI, STIR, and T2-Dixon (fat-only and water-only images). Skeletal metastases were evaluated in each sequence. Results were compared between the T1-STIR combination and T2-Dixon fat and water reconstructions. Results: The sensitivity of fat and water reconstructions from a single T2-Dixon in the detection of lytic skeletal metastases was marginally superior to a combination of T1WI and STIR sequences (0–7%). Detection of mixed lesions demonstrated equally high sensitivity in both protocols. Sclerotic metastases detection in WB-MRI showed low sensitivity in both protocols. However, specificity surpassed 95% for all lesion types in both protocols. Overall image quality was favored (in 87–90% of patients) in T2-Dixon images. The overall estimated acquisition timing using T2-Dixon appeared to be approximately half that of the standard T1-STIR combination. Conclusions: WB-MRI using T2-Dixon fat and water reconstructions showed similar accuracy to T1WI and STIR combination in the evaluation of skeletal metastases in patients with primary solid cancers with significantly shorter acquisition time. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
25. A comprehensive molecular characterization of a claudin-low luminal B breast tumor.
- Author
-
Giovannini, Sara, Smirnov, Artem, Concetti, Livia, Scimeca, Manuel, Mauriello, Alessandro, Bischof, Julia, Rovella, Valentina, Melino, Gerry, Buonomo, Claudio Oreste, Candi, Eleonora, and Bernassola, Francesca
- Subjects
- *
APOLIPOPROTEIN B , *RNA editing , *ESTROGEN receptors , *BREAST tumors , *BREAST cancer - Abstract
Breast cancer is the most common cause of death from cancer in women. Here, we present the case of a 43-year-old woman, who received a diagnosis of claudin-low luminal B breast cancer. The lesion revealed to be a poorly differentiated high-grade infiltrating ductal carcinoma, which was strongly estrogen receptor (ER)/progesterone receptor (PR) positive and human epidermal growth factor receptor (HER2) negative. Her tumor underwent in-depth chromosomal, mutational and gene expression analyses. We found a pathogenic protein truncating mutation in the TP53 gene, which is predicted to disrupt its transcriptional activity. The patient also harbors germline mutations in some mismatch repair (MMR) genes, and her tumor displays the presence of immune infiltrates, high tumor mutational burden (TMB) status and the apolipoprotein B mRNA editing enzyme catalytic polypeptide 3 (APOBEC3) associated signatures, which, overall, are predictive for the use of immunotherapy. Here, we propose promising prognostic indicators as well as potential therapeutic strategies based on the molecular characterization of the tumor. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
26. A Randomized Controlled Trial of a Culturally Adapted, Community-Based, Remotely Delivered Mindfulness Program for Latinx Patients With Breast Cancer is Acceptable and Feasible While Reducing Anxiety.
- Author
-
Juarez-Reyes, Maria, Martinez, Erica, Xiao, Lan, and Goldman Rosas, Lisa
- Subjects
ANXIETY prevention ,COMMUNITY health services ,SCALE analysis (Psychology) ,RESEARCH funding ,CENTER for Epidemiologic Studies Depression Scale ,MINDFULNESS ,EVALUATION of human services programs ,CULTURE ,BREAST tumors ,HISPANIC Americans ,STATISTICAL sampling ,QUESTIONNAIRES ,PILOT projects ,PSYCHOLOGICAL adaptation ,RANDOMIZED controlled trials ,DESCRIPTIVE statistics ,TELEMEDICINE ,YOGA ,ONLINE education ,SPIRITUALITY ,MEDITATION ,VIDEOCONFERENCING ,CANCER patient psychology ,CONFIDENCE intervals ,DATA analysis software - Abstract
Background/Objective: Few Spanish mindfulness interventions have been evaluated in Latinx patients with cancer. We culturally adapted a mindfulness intervention for Spanish speaking Latinx patients. The objective was to measure feasibility and acceptability as primary outcomes, with changes in anxiety, depression, and sleep as secondary outcomes. Method: Spanish-speaking Latinx patients with breast cancer (n = 31) were randomized, between April 2021 and May 2022 to either intervention or wait-list control groups. The mindfulness intervention consisted of 6-weekly 1.5-hour sessions remotely delivered by a novice facilitator. Cultural adaptations included language, metaphor, goal, concept, trauma informed, and acknowledgement of spirituality. Feasibility was benchmarked as 75% of participants attending their first session, 75% of participants completing 4 of 6 sessions, and scoring ≥ 4 on a 5-point Likert feasability scale measuring ability to implement changes after 6-weeks. Acceptability was measured as scoring ≥ 4 on a 5-point Likert scale measuring usefulness and relevance of the mindfulness intervention for each session. An intention-to-treat, linear mixed model with repeated measures analysis examined changes in anxiety, depression, and sleep at week 6 and 18 (3 months post intervention). Results: All three feasibility benchmarks were met with 75% of first session attendance, 96% of participants completing 4 of 6 sessions, and 94% scoring ≥ 4, on the feasibility scale (Mean (SD) = 4.3 (0.6)). Acceptability scores for both usefulness and relevance questions were ≥ 4 across all 6 sessions. Anxiety was significantly reduced at 3 months (−3.6 (CI -6.9, −0.2), P =.04), but is of unclear clinical significance given the small change. Depression scores declined, but not significantly, and there were no changes in sleep. Conclusion: This culturally adapted, remotely delivered mindfulness intervention using a novice facilitator was acceptable and feasible and demonstrated associated reductions in anxiety amongst Spanish speaking Latinx patients with breast cancer. Trial Registration: ClinicalTrials.gov ID# NCT04834154. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
27. Validity, reliability, responsiveness, and clinically meaningful change threshold estimates of the National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy-Breast Cancer Symptom Index (NFBSI-16).
- Author
-
Clarke, Nathan A., Wong, Brendon, Lawrance, Rachael, Ingelgård, Anders, Griebsch, Ingolf, Cella, David, and Trigg, Andrew
- Subjects
STATISTICAL correlation ,STATISTICAL models ,REPEATED measures design ,RECEIVER operating characteristic curves ,RESEARCH funding ,BREAST tumors ,RESEARCH evaluation ,RESEARCH methodology evaluation ,DESCRIPTIVE statistics ,PSYCHOMETRICS ,STATISTICAL reliability ,ONE-way analysis of variance ,HEALTH outcome assessment ,COMPARATIVE studies ,CONFIDENCE intervals ,SENSITIVITY & specificity (Statistics) ,EVALUATION - Abstract
Background: Breast cancer is one of the most common cancers in women. Patient-reported outcome measures are used to evaluate patients' health-related quality of life in clinical breast cancer studies. This study evaluated the structure, validity, reliability, and responsiveness of the National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy-Breast Cancer Symptom Index (NFBSI-16) subscales in a clinical trial featuring patients with advanced/metastatic breast cancer (aBC), and estimated NFBSI-16 meaningful change thresholds. Methods: Data from 101 patients with aBC enrolled in a phase II trial (Xenera-1) were included for psychometric evaluation of the NFBSI-16. Subscale structure was evaluated by assessing inter-item correlations, item-total correlations, and internal consistency (cycles 2 and 5). Validity was assessed using scale-level convergent validity (cycles 2 and 5) and known-groups (Baseline). Reliability was analysed via test-retest at cycles 3–4, and responsiveness to improvement and worsening was evaluated at cycles 5, 7, and 9. Meaningful change thresholds were estimated using anchor-based methods (supported by distribution-based methods) at cycles 5, 7, and 9. Results: NFBSI-16 internal consistency was acceptable, but item-total correlations suggested that its subscales and the GP5 item (side-effect of treatment) scores may be preferred over a total score. Convergent and known-groups evidence supported NFBSI-16 validity. Test-retest reliability was good to excellent for Total and DRS-P (disease-related symptoms: physical) scales, and moderate for the GP5 item. Responsiveness to worsening was generally demonstrated, but responsiveness to improvement could not be demonstrated due to limited observed improvement. Anchor-based meaningful change thresholds were estimated for DRS-P and Total scores. Conclusion: This study provides evidence that the NFBSI-16 has desirable psychometric properties for use in clinical studies in aBC. It also provides estimates of group- and individual-level meaningful change thresholds to facilitate score interpretation in future aBC research. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
28. Iterative qualitative approach to establishing content validation of a patient-reported outcome measure for arm lymphedema: the LYMPH-Q Upper Extremity Module.
- Author
-
Kaur, Manraj N., Cornacchi, Sylvie D., Tsangaris, Elena, Poulsen, Lotte, Beelen, Louise M., Bordeleau, Louise, Zhong, Toni, Jorgensen, Mads Gustaf, Sorensen, Jens Ahm, Mehrara, Babak, Dayan, Joseph, Pusic, Andrea L., and Klassen, Anne F.
- Subjects
LYMPHEDEMA ,RISK assessment ,ARM ,QUALITATIVE research ,RESEARCH evaluation ,BREAST tumors ,INTERVIEWING ,WORK-life balance ,DESCRIPTIVE statistics ,RESEARCH methodology ,QUALITY of life ,HEALTH outcome assessment ,DISEASE risk factors ,DISEASE complications - Abstract
Background: Breast cancer-related lymphedema (BRCL) is one of the most common causes of upper extremity (UE) lymphedema in developed nations and substantially impacts health-related quality of life. To advance our understanding of the epidemiology and treatment of BRCL, rigorously developed and validated patient-reported outcome measures (PROMs) are needed. This study aimed to demonstrate the iterative content validity of a modular UE lymphedema-specific PROM called the LYMPH-Q UE module. Methods: A multi-step iterative qualitative approach was used. Semi-structured interview data from in-depth qualitative interviews with adult women (18 years and older) with BCRL were used to develop the first set of the LYMPH-Q UE scales. The content validity of these scales was demonstrated with patient and clinician feedback. Over the course of cognitive debriefing interviews, additional concepts of lymphedema worry and impact on work were identified as missing from the LYMPH-Q UE module. Subsequently, two new qualitative studies (a focus group and in-depth concept elicitation interviews with patients) were conducted, and two new scales were developed to measure lymphedema worry and impact on work life and their content validity was demonstrated. Results: Qualitative data from in-depth and cognitive interviews with 15 (age 40–74 years) and 16 (age 38–74 years) women with BRCL, respectively, and feedback from 12 clinical experts, were used to develop and demonstrate the content validity of six LYMPH-Q UE scales measuring symptoms, function, appearance, psychological, information, and arm sleeve. Additionally, data from in-depth interviews with 12 (age 35–72 years) women with UE lymphedema and four focus groups (n = 16 women; age 35–74 years) was used to develop and assess the content validity of two new LYMPH-Q UE scales measuring lymphedema worry and impact on work life. The content validity of the previously established six scales was also demonstrated in these subsequent qualitative studies. Conclusion: The LYMPH-Q UE is a modular PROM developed using international guidelines for PROM development and can be used in clinical practice, research, and quality improvement to enhance patient-centered shared decision-making. This study's innovative and iterative approach to content validation demonstrates that the LYMPH-Q UE is a comprehensive measure that includes important concepts relevant to patients with UE lymphedema. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
29. Rare Earth Nanoprobes for Targeted Delineation of Triple Negative Breast Cancer and Enhancement of Radioimmunotherapy.
- Author
-
Ming, Zi‐He, Zhang, Yong‐Qu, Song, Liang, Chen, Min, Lin, Lin‐Ling, He, Yue‐Yang, Liu, Wan‐Ling, Zhu, Yuan‐Yuan, Zhang, Yun, and Zhang, Guo‐Jun
- Subjects
- *
TRIPLE-negative breast cancer , *TUMOR-infiltrating immune cells , *BREAST tumors , *RADIOIMMUNOTHERAPY , *IMAGING systems , *BREAST - Abstract
Radiotherapy demonstrates a synergistic effect with immunotherapy by inducing a transformation of "immune cold" tumors into "immune hot" tumors in triple negative breast cancer (TNBC). Nevertheless, the effectiveness of immunotherapy is constrained by low expression of tumor‐exposed antigens, inadequate inflammation, and insufficient tumor infiltrating lymphocyte (TILs). To address this predicament, novel lutecium‐based rare earth nanoparticles (RENPs) are synthesized with the aim of amplifying radiation effect and tumor immune response. The nanoprobe is characterized by neodymium‐based down‐conversion fluorescence, demonstrating robust photostability, biocompatibility, and targetability. The conjugation of RENPs with a CXCR4 targeted drug enables precise delineation of breast tumors using a near‐infrared imaging system and improves radiation efficacy via lutetium‐based radio‐sensitizer in vivo. Furthermore, the study shows a notable enhancement of immune response through the induction of immunogenic cell death and recruitment of TILs, resulting in the inhibition of tumor progression both in vitro and in vivo models following the administration of nanoparticles. Hence, the novel multifunctional nanoprobes incorporating various lanthanide elements offer the potential for imaging‐guided tumor delineation, radio‐sensitization, and immune activation post‐radiation, thus presenting an efficient radio‐immunotherapeutic approach for TNBC. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
30. A region-confined PROTAC nanoplatform for spatiotemporally tunable protein degradation and enhanced cancer therapy.
- Author
-
Gao, Jing, Jiang, Xingyu, Lei, Shumin, Cheng, Wenhao, Lai, Yi, Li, Min, Yang, Lei, Liu, Peifeng, Chen, Xiao-hua, Huang, Min, Yu, Haijun, Xu, Huixiong, and Xu, Zhiai
- Subjects
REACTIVE oxygen species ,HEAD & neck cancer ,TUMOR growth ,PROTEOLYSIS ,BREAST tumors - Abstract
The antitumor performance of PROteolysis-TArgeting Chimeras (PROTACs) is limited by its insufficient tumor specificity and poor pharmacokinetics. These disadvantages are further compounded by tumor heterogeneity, especially the presence of cancer stem-like cells, which drive tumor growth and relapse. Herein, we design a region-confined PROTAC nanoplatform that integrates both reactive oxygen species (ROS)-activatable and hypoxia-responsive PROTAC prodrugs for the precise manipulation of bromodomain and extraterminal protein 4 expression and tumor eradication. These PROTAC nanoparticles selectively accumulate within and penetrate deep into tumors via response to matrix metalloproteinase-2. Photoactivity is then reactivated in response to the acidic intracellular milieu and the PROTAC is discharged due to the ROS generated via photodynamic therapy specifically within the normoxic microenvironment. Moreover, the latent hypoxia-responsive PROTAC prodrug is restored in hypoxic cancer stem-like cells overexpressing nitroreductase. Here, we show the ability of region-confined PROTAC nanoplatform to effectively degrade BRD4 in both normoxic and hypoxic environments, markedly hindering tumor progression in breast and head-neck tumor models. Antitumor performance of PROteolysis-TArgeting Chimeras (PROTACs) is limited by their targeting ability and retention to tumor sites. Here the authors design the reactive oxygen species (ROS)-activatable and hypoxia-responsive PROTAC nanoparticles with selective penetration into tumors for degradation of BRD4 to suppress breast and head and neck cancer progression. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
31. Use of NHS PREDICT Tool and Prognostic Factors for Survival in Patients with Breast Cancer.
- Author
-
Koh CHEE KEONG, WAN ZAIN, Wan Zainira, ZAHARI, Zalina, YAHYA, Maya Mazuwin, and MOHAMAD, Hussain
- Subjects
- *
BREAST cancer prognosis , *NATIONAL health services , *RISK assessment , *PREDICTION models , *SURVIVAL rate , *DEATH , *RESEARCH methodology evaluation , *BREAST tumors , *RETROSPECTIVE studies , *DESCRIPTIVE statistics , *CANCER patients , *SURVIVAL analysis (Biometry) , *CONFIDENCE intervals , *TUMOR classification , *OVERALL survival ,MORTALITY risk factors - Abstract
Aim: The PREDICT tool is used to estimate survival in breast cancer patients according to the types of treatment given. This study aimed to assess the accuracy of the PREDICT tool and identify the prognostic factors for survival in patients with breast cancer. Material and Methods: A retrospective study was performed based on data collected from the Hospital Sultanah Nur Zahirah, Terengganu, Malaysia. All female patients diagnosed with stage I to IV breast cancer were identified from the year 2011 to 2017. Results: Based on data from 355 eligible patients, the predicted and observed 5-year overall survival rates were 75.8% and 75.2%, respectively. The model performed fairly well, with the area under the curve (AUC) of 0.747 (95% confidence interval (CI): 0.69-0.81) in the predicted 5-year overall survival. Among the 585 patients diagnosed with stage I to IV breast cancer, stage at the presentation (stage III hazard ratio (HR): 5.80, 95% CI: 1.69-19.94, p=0.005, stage IV HR: 10.61, 95% CI: 3.09-36.49, p<0.001), without surgical treatment (HR: 2.29, 95% CI: 1.73-3.00, p<0.001), without radiotherapy (HR: 1.92, 95% CI: 1.41-2.62, p<0.001), and without neoadjuvant chemotherapy (HR: 0.63, 95% CI: 0.47-0.86, p=0.003) were associated with death in breast cancer patients. Conclusion: The PREDICT tool accurately estimated the 5-year overall survival in the study center. It might serve as a useful prognostication tool during consultation. Late stages of the disease, patients without surgical treatment, and patients without radiotherapy were associated with a higher risk of death in breast cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
32. Evaluation of 5′-tRF-His-GTG As a Molecular Biomarker in Breast Cancer Diagnoses and Prognosis.
- Author
-
Tang, Xun, Wu, Jun, Chen, Yan, Wang, Daojuan, Wang, Tingyu, Weng, Yajing, Zhu, Zhengquan, Peng, Rui, Wang, Yong, and Yan, Feng
- Subjects
- *
BREAST cancer prognosis , *BREAST tumor diagnosis , *RESEARCH funding , *BREAST tumors , *TUMOR markers , *CELLULAR signal transduction , *GENE expression , *IMMUNOHISTOCHEMISTRY , *EPIDERMAL growth factor , *HISTOLOGICAL techniques , *TRANSFER RNA , *MOLECULAR biology , *GENOMES - Abstract
Background: Breast cancer (BC) is the most prevalent cancer among women worldwide. Although advances have been made in the identification of predictive biomarkers, current options for early diagnosis and prognostic analysis are still suboptimal. Recently, transfer-RNA-derived RNA fragments (tRFs) have emerged as a class of small noncoding RNAs that play a role in the cancer progression. The authors aimed to identify a specific class of tRFs as a molecular marker for BC diagnosis and prognosis in clinical management. Methods: The levels of 5′-tRF-His-GTG were quantified in BC tissue (n = 101) and inflammatory normal breast tissue (n = 22) using in situ hybridization. Clinicopathological parameters were obtained, including age, tumor node metastasis stage, hormone receptor status, histopathological grade, lymphovascular invasion, and recurrence. The correlation between the expression of 5′-tRF-His-GTG and these parameters in different BC subtypes was analyzed. Patient death and cancer progression were regarded as clinical endpoints in the survival analysis. Gene Ontology (GO) enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis were also performed to predict the involvement in pivotal biological process. Results: The expression of 5′-tRF-His-GTG was significantly downregulated in BC tissues and was in connection with T stage in human epidermal growth factor 2-positive and basal-like BC, as well as N stage and histopathological grade in luminal BC. Patients with low expression of 5′-tRF-His-GTG had a poor overall survival rate. Statistics of GO and KEGG pathway revealed that cation channel activity, protein catabolic process, response to temperature stimulus, cell cycle, focal adhesion, and glycerophospholipid metabolism were significantly enriched. Conclusions: This study suggests that the assessment of 5′-tRF-His-GTG expression could serve as a novel biomarker for individual diagnosis and prognosis in BC. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
33. Exosome-Derived MicroRNA-221-3p Desensitizes Breast Cancer Cells to Adriamycin by Regulating PIK3r1-Mediated Glycose Metabolism.
- Author
-
Hong, Xiaolu and Pan, Xiaoping
- Subjects
- *
FLOW cytometry , *DRUG resistance in cancer cells , *T-test (Statistics) , *DATA analysis , *RESEARCH funding , *BREAST tumors , *MICRORNA , *APOPTOSIS , *CELL proliferation , *QUANTITATIVE research , *REVERSE transcriptase polymerase chain reaction , *LACTATE dehydrogenase , *FLUORESCENT antibody technique , *CELL lines , *GENES , *BLOOD sugar , *GENE expression , *CELL culture , *DOXORUBICIN , *CYTOMETRY , *ONE-way analysis of variance , *STATISTICS , *EXOSOMES - Abstract
Background: Cancer-derived exosomes facilitate chemoresistance by transferring RNAs, yet their role in exosomal microRNA-221-3p (miR-221-3p) regulation of adriamycin resistance in breast cancer (BC) remains unclear. Methods: Adriamycin-resistant BC cells were developed from MCF-7 and MDA-MB-231 cells by incremental adriamycin exposure. The miR-221-3p levels were quantified by quantitative reverse transcription-polymerase chain reaction. Subsequently, exosomes were isolated and incubated with BC cells, and exosome-mediated adriamycin sensitivity was evaluated using Cell Counting Kit-8, colony formation, and flow cytometry assays. Sensitive cells were cocultured with miR-221-3p inhibitor-treated cells to assess adriamycin resistance. Moreover, the interaction between miR-221-3p and phosphoinositide-3-kinase regulatory subunit 1 (PIK3R1) was validated using a dual luciferase reporter gene assay. Mimics and inhibitors were used to determine the effects of miR-221-3p on adriamycin resistance. Results: Elevated levels of miR-221-3p expression were observed in adriamycin-resistant BC cells and exosomes. Sensitive cells were cocultured with exosomes from resistant cells, resulting in increased half-maximal inhibitory concentration value and proliferation, and reduced adriamycin-induced apoptosis. However, the effects of coculturing sensitive cells with adriamycin-resistant cells were significantly weakened by miR-221-3p inhibitor transfection in adriamycin-resistant cells. PIK3R1 was found to be a target of miR-221-3p, and miR-221-3p mimics enhanced adriamycin resistance in sensitive cells. miR-221-3p inhibitors increased the expression of PIK3R1, p-AKT, c-Myc, HK2, and PKM2, decreased FOXO3 expression, and weakened the adriamycin resistance in resistant cells. Conclusions: miR-221-3p can be transferred between BC cells through exosomes. High levels of miR-221-3p were found to target PIK3R1 and promoted adriamycin resistance in BC cells. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
34. RNA Interference Induces BRCA1 Gene Methylation and Increases the Radiosensitivity of Breast Cancer Cells.
- Author
-
Shi, Yuebin, Huang, Rui, Zhang, Yong, Feng, Qiang, Pan, Xinyan, and Wang, Li
- Subjects
- *
CYTOLOGY , *BLOOD irradiation , *BRCA genes , *COLONY-forming units assay , *RESEARCH funding , *BREAST tumors , *PLASMIDS , *TUMOR markers , *CELL lines , *DNA methylation , *GENE expression , *HISTONES , *MESSENGER RNA , *RNA methylation , *WESTERN immunoblotting , *SEQUENCE analysis - Abstract
Purpose: To investigate the relationship between breast cancer susceptibility gene-1 (BRCA1) gene methylation and the radiosensitivity of breast cancer. Materials and Methods: The authors studied three breast cancer cell lines: MDA-MB-435, MDA-MB-231, and MCF-7 cells. They constructed five short hairpin RNAs (shRNAs) and five small interfering RNAs to target selected promoter loci and initiate sequence-specific methylation in breast cancer cells. Pyrosequencing was used to analyze the state of DNA methylation. Quantitative real-time polymerase chain reaction was used to detect BRCA1 mRNA expression and RNA-directed DNA methylation (RdDM)-related gene expression. Western blotting was performed to analyze BRCA1 protein expression. Colony formation assays and γ-histone H2A foci formation assays were conducted to assess the surviving fraction (SF) and double-strand break (DSB) repair ability of cells after irradiation. Results: The authors constructed five strains of lentivirus vectors and five plasmid vectors targeting BRCA1 promoter region. In MDA-MB-435 cells, lentivirus-mediated RNA interference targeting Site 1 of BRCA1 increased the methylation levels of BRCA1 and reduced BRCA1 mRNA and protein expression. The SF and the ability to repair DNA DSBs were reduced in the combined LV-BRCA1RNAi-Site 1 infection and irradiation group. Conclusions: The authors' findings suggest that the shRNA suppressed the expression levels of the BRCA1 gene and reduced the SF and DNA repair ability of cells after irradiation through RdDM. In summary, the radiosensitivity of breast cancer cells may correlate with BRCA1 methylation. Advances in Knowledge: The authors first utilized a lentivirus-based shRNA-mediated specific-sequence DNA methylation of the BRCA1 gene mediated by RdDM. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
35. Nested Biofabrication: Matryoshka‐Inspired Intra‐Embedded Bioprinting.
- Author
-
Alioglu, Mecit Altan, Yilmaz, Yasar Ozer, Singh, Yogendra Pratap, Nagamine, Momoka, Celik, Nazmiye, Kim, Myoung Hwan, Pal, Vaibhav, Gupta, Deepak, and Ozbolat, Ibrahim T.
- Subjects
- *
BIOPRINTING , *BLOOD vessels , *BREAST tumors , *TISSUE engineering , *MANUFACTURING industries , *BREAST - Abstract
Engineering functional tissues and organs remains a fundamental pursuit in bio‐fabrication. However, the accurate constitution of complex shapes and internal anatomical features of specific organs, including their intricate blood vessels and nerves, remains a significant challenge. Inspired by the Matryoshka doll, here a new method called "Intra‐Embedded Bioprinting (IEB)" is introduced building upon existing embedded bioprinting methods. a xanthan gum‐based material is used which served a dual role as both a bioprintable ink and a support bath, due to its unique shear‐thinning and self‐healing properties. IEB's capabilities in organ modeling, creating a miniaturized replica of a pancreas using a photocrosslinkable silicone composite is demonstrated. Further, a head phantom and a Matryoshka doll are 3D printed, exemplifying IEB's capability to manufacture intricate, nested structures. Toward the use case of IEB and employing an innovative coupling strategy between extrusion‐based and aspiration‐assisted bioprinting, a breast tumor model that included a central channel mimicking a blood vessel, with tumor spheroids bioprinted in proximity is developed. Validation using a clinically‐available chemotherapeutic drug illustrated its efficacy in reducing the tumor volume via perfusion over time. This method opens a new way of bioprinting enabling the creation of complex‐shaped organs with internal anatomical features. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
36. Postmenopausal women treated for breast cancer with insulin resistance: clinical, analytical, cross-sectional.
- Author
-
Orsatti, Claudio Lera, Orsatti, Fabio Lera, De Souza, João Pedro Esteves Alves, de Araujo Brito Buttros, Daniel, and Nahas, Eliana Aguiar Petri
- Subjects
- *
CROSS-sectional method , *WOMEN , *RESEARCH funding , *BREAST tumors , *CLINICAL medicine research , *STATISTICAL sampling , *POSTMENOPAUSE , *DESCRIPTIVE statistics , *MANN Whitney U Test , *CHI-squared test , *MULTIVARIATE analysis , *HEAT shock proteins , *INSULIN resistance , *RESEARCH , *CYTOKINES , *DATA analysis software , *SURVIVAL analysis (Biometry) , *ANTHROPOMETRY , *REGRESSION analysis - Abstract
This study aims to investigate the potential association between serum levels of cytokines, HSP60, HSP70 and IR (HOMA-IR) in postmenopausal women. We conducted a cross-sectional study involving 381 postmenopausal women, including 94 with a breast cancer diagnosis and 278 without. We analyzed anthropometric and laboratory measurements. Immunoassays were used to measure cytokines (TNF-α, IL-10, and IL-6) as well as heat shock proteins (HSP) 60 and 70 in the serum using the ELISA technique. Women diagnosed with breast cancer showed higher levels of HOMA-IR, IL-6, TNF, and HSP60, and lower levels of IL-10 and HSP70 compared to women without cancer. An association was found between HSP70 and HOMA-IR only in women with breast cancer (β = 0.22, p =.030; without cancer: β = 0.04, p =.404), regardless of age, waist circumference, smoking, and physical activity. No associations were observed between cytokines, HSP60, and HOMA-IR in both groups of women. HSP70 is positively associated with IR in women diagnosed with breast cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
37. Clear cell hidradenoma of the breast with MAML2 gene rearrangement.
- Author
-
Luo, Li and Hu, Yanping
- Subjects
- *
FLUORESCENCE in situ hybridization , *GENE rearrangement , *STAINS & staining (Microscopy) , *BREAST tumors , *IMMUNOSTAINING - Abstract
Clear cell hidradenoma is a rare benign tumor of the breast, its origin and pathogenesis are controversial. We have experienced a case of breast clear cell hidradenoma with mastermind like transcriptional coactivator 2 (MAML2) gene rearrangement. The patient found a painless mass with a hard texture in the left breast areola without nipple discharge. Microscopically, the tumor was cystic and solid, locally arranged in a glandular structure, covered by single cuboidal cells; it was composed of clear cells, epidermoid cells, and basaloid cells; there were no necrosis or mitotic figures. Immunohistochemical staining showed that the tumor cells positively expressed low‐molecular cytokeratin 7, low‐molecular cytokeratins (Cam5.2), high‐molecular cytokeratin 5/6, cytokeratin 14, CD117, and p63; and did not express calponin, and smooth muscle myosin heavy chain. The cuboidal cells were positive for SOX10 but negative for p63. Additionally, periodic acid‐Schiff reaction showed purple‐red granules in the tumor cytoplasm, but Alcian blue staining showed no blue mucus in the cytoplasm. The split signals of MAML2 gene were detected by fluorescence in situ hybridization. Subtle histological and immunophenotypical differences may help to distinguish breast clear cell hidradenoma from common breast tumors. Furthermore, the MAML2 gene rearrangement may be a molecular genetic characteristic of breast clear cell hidradenoma. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
38. Cancer rehabilitation services for older women with breast cancer: Impact on health‐related quality of life outcomes.
- Author
-
Pergolotti, Mackenzi, Wood, Kelley C., Kendig, Tiffany, Love, Kim, and Mayo, Stacye
- Subjects
- *
PHYSICAL therapy , *COMMUNITY health services , *MEDICAL care research , *HEALTH status indicators , *BREAST tumors , *AT-risk people , *SCIENTIFIC observation , *DESCRIPTIVE statistics , *RETROSPECTIVE studies , *OCCUPATIONAL therapy , *QUALITY of life , *MEDICAL records , *ACQUISITION of data , *WOMEN'S health , *HEALTH outcome assessment , *CANCER patient rehabilitation , *OLD age - Abstract
Background: Older breast cancer survivors (BCS, age ≥ 65) are vulnerable to experiencing persistent symptoms and associated declines in health‐related quality of life (HRQOL). In research trials, cancer rehabilitation interventions (physical or occupational therapy, PT/OT) have been shown to enhance HRQOL, but the impact of community‐based PT/OT services for older BCS is unknown. We performed a retrospective, observational study to better understand the impact of PT/OT services on the HRQOL of older BCS. Methods: Outcomes and covariates were extracted from the outpatient rehabilitation medical record. HRQOL outcomes included: PROMIS® global physical health (GPH), global mental health (GMH), physical function (PF), and ability to participate in social roles and activities (SRA). Linear mixed‐effect models were used to examine change in HRQOL outcomes and explore the influence of patient age and service type (PT/OT). ICD‐10 codes were examined and compared between service types to describe the impairments treated. Results: PT/OT cases (N = 694) were 71.79 ± 5.44 years old and participated in a median of 11 visits (IQR: 7.0–17.25) over 9.71 weeks (IQR: 6.29–15.29). Most (84.4%) attended PT (n = 579; 84%) versus OT (n = 115; 16%). Overall, significant improvement was observed in each HRQOL outcome (GPH: +3.00, p < 0.001; GMH: +1.80, p < 0.001; PF: +1.97, p < 0.001; SRA: +2.34, p < 0.001). Service type influenced only GPH (p = 0.041); mean improvement was +3.24 (SE: 0.290, p < 0.001) for PT cases and + 1.78 for OT cases (SE: 0.651, p = 0.007). PT cases commonly received treatment for weakness/atrophy, pain, walking, and posture; OT cases commonly received treatment for lymphedema and scarring/fibrosis. No age effects were observed. Conclusions: In this large study of older BCS who participated in community‐based PT/OT services across the United States, we observed significant improvements in HRQOL outcomes that are important to older BCS and their providers. Although more research is needed, these findings suggest that improved access to PT/OT could help address unmet HRQOL needs among this population. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
39. The Performance and Clinical Applicability of HER2 Digital Image Analysis in Breast Cancer: A Systematic Review.
- Author
-
Dunenova, Gauhar, Kalmataeva, Zhanna, Kaidarova, Dilyara, Dauletbaev, Nurlan, Semenova, Yuliya, Mansurova, Madina, Grjibovski, Andrej, Kassymbekova, Fatima, Sarsembayev, Aidos, Semenov, Daniil, and Glushkova, Natalya
- Subjects
- *
BREAST tumors , *DIGITAL diagnostic imaging , *DESCRIPTIVE statistics , *SYSTEMATIC reviews , *MEDLINE , *DIGITAL image processing , *ONLINE information services , *ALGORITHMS - Abstract
Simple Summary: HER2-positive breast cancer occurs in 15–30% of cases and has a poor prognosis. Digital image analysis of HER2 is promising, but its implementation in real clinical practice remains unclear. This systematic review evaluates the effectiveness of digital image analysis algorithms for HER2 in breast cancer and their performance, with a focus on testing them in real-world clinical settings. The authors aim to assess the applicability of these algorithms in practical clinical scenarios. By analyzing 25 papers from the period 2013–2024 and emphasizing mostly deep learning approaches, the review underscores the importance of standardized evaluation criteria, study designs tailored for clinical applications, and clinical validation. While direct evidence of clinical application was not found, the findings aim to guide future research and the implementation of digital image analysis in breast cancer diagnosis within clinical settings, potentially impacting the research community by advancing algorithmic applications in real clinical practice. This systematic review aims to address the research gap in the performance of computational algorithms for the digital image analysis of HER2 images in clinical settings. While numerous studies have explored various aspects of these algorithms, there is a lack of comprehensive evaluation regarding their effectiveness in real-world clinical applications. We conducted a search of the Web of Science and PubMed databases for studies published from 31 December 2013 to 30 June 2024, focusing on performance effectiveness and components such as dataset size, diversity and source, ground truth, annotation, and validation methods. The study was registered with PROSPERO (CRD42024525404). Key questions guiding this review include the following: How effective are current computational algorithms at detecting HER2 status in digital images? What are the common validation methods and dataset characteristics used in these studies? Is there standardization of algorithm evaluations of clinical applications that can improve the clinical utility and reliability of computational tools for HER2 detection in digital image analysis? We identified 6833 publications, with 25 meeting the inclusion criteria. The accuracy rate with clinical datasets varied from 84.19% to 97.9%. The highest accuracy was achieved on the publicly available Warwick dataset at 98.8% in synthesized datasets. Only 12% of studies used separate datasets for external validation; 64% of studies used a combination of accuracy, precision, recall, and F1 as a set of performance measures. Despite the high accuracy rates reported in these studies, there is a notable absence of direct evidence supporting their clinical application. To facilitate the integration of these technologies into clinical practice, there is an urgent need to address real-world challenges and overreliance on internal validation. Standardizing study designs on real clinical datasets can enhance the reliability and clinical applicability of computational algorithms in improving the detection of HER2 cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
40. A Retrospective Analysis of Breast Cancer Mortality among Jewish and Muslim Arab Women in Israel: The Role of Sociodemographic Factors.
- Author
-
Pinchas-Mizrachi, Ronit and Bouhnik, Dan
- Subjects
- *
RISK assessment , *RESEARCH funding , *BREAST tumors , *RESIDENTIAL patterns , *PSYCHOLOGY of women , *CAUSES of death , *RETROSPECTIVE studies , *FAMILIES , *MUSLIMS , *PSYCHOLOGY of Jews , *ARABS , *MEDICAL records , *ACQUISITION of data , *BIRTHPLACES , *SOCIODEMOGRAPHIC factors , *CANCER patient psychology , *HEALTH equity , *SOCIAL classes - Abstract
Simple Summary: Breast cancer is a major health concern worldwide, with mortality rates varying between ethnic groups. In Israel, Jewish and Muslim Arab women have different socioeconomic backgrounds and lifestyle factors that may influence breast cancer outcomes. This study investigates disparities in breast cancer mortality between these two groups and examines how factors such as number of children, socioeconomic status, and place of residence affect mortality rates. By analyzing data from over 800,000 Israeli women over a 30-year period, the researchers aim to understand the complex interplay among ethnicity, sociodemographic factors, and breast cancer mortality. The findings of this study could help identify key risk factors and protective elements specific to each ethnic group. This information is crucial for developing targeted intervention programs to reduce disparities and improve breast cancer outcomes for both Jewish and Muslim Arab women in Israel. Breast cancer mortality rates vary across ethnic groups in Israel, where protective factors such as high fertility and breastfeeding rates may be moderated by socioeconomic factors and mammography rates. We aim to investigate disparities in breast cancer mortality between Jewish and Muslim Arab women in Israel and examine how sociodemographic variables and number of children are associated with mortality. Our retrospective follow-up study uses data from the Israeli Central Bureau of Statistics and multivariable Cox regression models, adjusting for age, number of children, country of origin, locality size, and socioeconomic status. Compared to Jewish women, Muslim Arab women exhibited lower breast cancer mortality rates. However, after adjusting for multiple sociodemographic variables, no significant differences persisted between Jewish and Muslim Arab women. Having more than three children was associated with lower mortality among Muslim Arab women but not among Jewish women. European/American origin, larger localities, and medium socioeconomic status were associated with higher mortality. Sociodemographic factors may therefore explain the disparities in breast cancer mortality between Jewish and Muslim Arab women in Israel. Targeted intervention programs that consider the unique characteristics and risk factors of different ethnic groups are needed to reduce disparities and improve outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
41. Association between Cognitive Function and Physical Function, Frailty, and Quality of Life in Older Breast Cancer Survivors.
- Author
-
Von Ah, Diane, Rio, Carielle Joy, Carter, Allie, Perkins, Susan M., Stevens, Erin, Rosko, Ashley, Davenport, Ashley, Kalady, Mathew, Noonan, Anne M., Crouch, Adele, Storey, Susan, Overcash, Janine, Han, Claire J., Yang, Yesol, Li, Haiying, and Saligan, Leorey N.
- Subjects
- *
COGNITIVE testing , *RESEARCH funding , *BREAST tumors , *FRAIL elderly , *DESCRIPTIVE statistics , *SURVEYS , *QUALITY of life , *MEMORY , *AGING , *CANCER patient psychology , *BODY movement , *REGRESSION analysis , *COMORBIDITY , *OLD age - Abstract
Simple Summary: This study examines the relationship between subjective and objective measures of cognitive function and physical function, frailty, and quality of life (QoL) in older breast cancer survivors. Older breast cancer survivors who reported concerns participated in online surveys that included assessment of patient-reported cognitive function, physical function, frailty, and QoL. Participants then completed objective tests assessing visuospatial working memory and sustained attention. A total of 219 breast cancer survivors completed the study. Overall, older breast cancer survivors with higher perceived cognitive impairment reported poorer physical functioning, increased frailty, and poorer QoL (p ≤ 0.001). Poorer visuospatial working memory and sustained attention exhibited increased frailty (p ≤ 0.001–0.01); while poorer sustained attention was associated with poorer physical function (p < 0.01). The findings of this study suggest a need for a thorough assessment of cognitive concerns and their associated outcomes in older breast cancer survivors. Background: Older cancer survivors in general are at greater risk for cancer-related cognitive impairment (CRCI), yet few studies have explored its association with health outcomes. This study examined the association between subjective and objective measures of cognitive function and physical function, frailty, and quality of life (QoL) among older breast cancer survivors. Materials and Methods: Older breast cancer survivors who reported cognitive concerns completed surveys on patient-reported cognitive function, physical function, frailty, and QoL as well as objective tests of visuospatial working memory and sustained attention. Data were analyzed using descriptive statistics and separate linear regression models. Results: A total of 219 female breast cancer survivors completed the study. Perceived cognitive abilities were associated with better physical function, frailty, and QoL (p ≤ 0.001) while cognitive concerns were negatively related with these metrics (p ≤ 0.001). Poorer visuospatial working memory and sustained attention were linked to increased frailty (p ≤ 0.001–0.01), whereas poorer sustained attention was associated with poorer physical function (p < 0.01). Conclusions: Older breast cancer survivors with perceived cognitive impairment and poorer cognitive performance reported poorer physical functioning, increased frailty, and poorer QoL. These findings underscore the importance of assessing cognitive concerns and their associated outcomes in older breast cancer survivors. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
42. Evaluation of the Mammalian Aquaporin Inhibitors Auphen and Z433927330 in Treating Breast Cancer.
- Author
-
Charlestin, Verodia, Tan, Elijah, Arias-Matus, Carlos Eduardo, Wu, Junmin, Miranda-Vergara, Maria Cristina, Lee, Mijoon, Wang, Man, Nannapaneni, Dharma T., Tennakoon, Parinda, Blagg, Brian S. J., Ashfeld, Brandon L., Kaliney, William, Li, Jun, and Littlepage, Laurie E.
- Subjects
- *
THERAPEUTIC use of antineoplastic agents , *PROTEINS , *CARRIER proteins , *CANCER invasiveness , *GOLD compounds , *MITOCHONDRIA , *RESEARCH funding , *RECEIVER operating characteristic curves , *BREAST tumors , *ANTINEOPLASTIC agents , *CELL physiology , *POLYMERASE chain reaction , *TRANSCRIPTION factors , *TAMOXIFEN , *DESCRIPTIVE statistics , *METASTASIS , *GENE expression , *MICE , *CELL lines , *EXPERIMENTAL design , *RNA , *IMMUNOHISTOCHEMISTRY , *ANIMAL experimentation , *MOLECULAR structure , *WESTERN immunoblotting , *DRUG efficacy , *CELL survival , *OVERALL survival , *PHARMACODYNAMICS , *CHEMICAL inhibitors - Abstract
Simple Summary: Aquaporins (AQPs) have emerged as potential predictors of response to cancer therapy and as targets for increasing sensitivity to treatment. However, systemic therapeutic inhibition using pan-AQP or AQP-specific inhibitors has not been characterized for efficacy in treating breast cancer or as a component of combination treatment. We evaluated AQP inhibition using established AQP inhibitors in cytotoxicity and pharmacologic assays. This study identified AQPs as a targetable vulnerability in breast cancer. AQP inhibitors can increase therapeutic efficacy, both as single agents and in a combination therapy strategy, in treating breast cancer progression and metastasis. These results provide significant insights that support the future development of improved AQP inhibitors. AQPs contribute to breast cancer progression and metastasis. We previously found that genetic inhibition of Aqp7 reduces primary tumor burden and metastasis in breast cancer. In this study, we utilized two AQP inhibitors, Auphen and Z433927330, to evaluate the efficacy of therapeutic inhibition of AQPs in breast cancer treatment. The inhibitors were evaluated in breast cancer for both cytotoxicity and metabolic stability assays across both murine and human breast cancer cell lines. Both AQP inhibitors also affected the expression of other AQP transcripts and proteins, which demonstrates compensatory regulation between AQP family members. As a single agent, Auphen treatment in vivo extended overall survival but did not impact primary or metastatic tumor burden. However, Auphen treatment made cells more responsive to chemotherapy (doxorubicin) or endocrine treatment (tamoxifen, fulvestrant). In fact, treatment with Tamoxifen reduced overall AQP7 protein expression. RNA-seq of breast cancer cells treated with Auphen identified mitochondrial metabolism genes as impacted by Auphen and may contribute to reducing mammary tumor progression, lung metastasis, and increased therapeutic efficacy of endocrine therapy in breast cancer. Interestingly, we found that Auphen and tamoxifen cooperate to reduce breast cancer cell viability, which suggests that Auphen treatment makes the cells more susceptible to Tamoxifen. Together, this study highlights AQPs as therapeutic vulnerabilities of breast cancer metastasis that are promising and should be exploited. However, the pharmacologic results suggest additional chemical refinements and optimization of AQP inhibition are needed to make these AQP inhibitors appropriate to use for therapeutic benefit in overcoming endocrine therapy resistance. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
43. Long-Term Oncologic Outcomes of Omitting Axillary Surgery in Breast Cancer Patients with Chest Wall Recurrence after Mastectomy.
- Author
-
Lim, Geok Hoon, Alcantara, Veronica Siton, Allen Jr., John Carson, Saffari, Seyed Ehsan, Tan, Veronique Kiak Mien, Tan, Kiat Tee Benita, Ngaserin, Sabrina, Tan, Su Ming, Leong, Lester Chee Hao, and Wong, Fuh Yong
- Subjects
- *
RISK assessment , *AXILLA , *CANCER relapse , *BREAST tumors , *AXILLARY lymph node dissection , *TREATMENT effectiveness , *RETROSPECTIVE studies , *DESCRIPTIVE statistics , *METASTASIS , *RESEARCH , *DUCTAL carcinoma , *MASTECTOMY , *CARCINOMA in situ , *DISEASE risk factors - Abstract
Simple Summary: The management of the axilla for post-mastectomy breast cancer patients who develop a chest wall recurrence (CWR) remains to be established. This study aimed to determine if omitting axillary staging surgery for these patients resulted in an increased risk of second recurrence. A total of 194 patients with CWR, with a median follow-up of 59.5 (IQR 27.3–105) months, were analysed. There was no statistically significant difference in second recurrences between patients with or without axillary surgery during the excision of the CWR. Background: The management of the axilla in breast cancer patients with isolated chest wall recurrence (CWR) after mastectomy remains controversial. Although sentinel lymph node biopsy (SLNB) for restaging is feasible, its role is unclear. We aimed to determine if the omission of axillary restaging surgery in female patients with operable presumably isolated CWRs could result in an increased risk of second recurrences. Methods: In this retrospective multicentre study, patients who developed CWRs were reviewed. We excluded patients with suspected or concomitant regional/distant metastases, bilateral cancers and patients without CWR surgery. Patients' demographics, pathological data and subsequent recurrences were collected from a prospective database and were compared between patients with axillary lymph node dissection (ALND) and/or SLNB versus no axillary operation at CWR. Findings: A total of 194 patients with CWRs were eligible. The median age at CWR was 56.0 (IQR 47.0–67.0) years old. At recurrence, 8 (4.1%), 5 (2.6%) and 181 (93.3%) patients had ALND, SLNB and no axillary operation, respectively. Patients with no axillary surgery during CWR were associated with, at primary cancer, a lower incidence of ductal carcinoma in situ as diagnosis (p = 0.007) and older age (p = 0.022). Subsequent ipsilateral axillary (p = 0.768) and second recurrences (p = 0.061) were not statistically different between patients with and without axillary surgery at CWR on median follow-up of 59.5 (IQR 27.3–105) months. Interpretation: In patients without evidence of concomitant regional or distant metastasis at CWR diagnosis, omission of axillary restaging surgery was not associated with an increased ipsilateral axillary or second recurrences on long-term follow-up. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
44. Artificial Intelligence in Detection, Management, and Prognosis of Bone Metastasis: A Systematic Review.
- Author
-
Papalia, Giuseppe Francesco, Brigato, Paolo, Sisca, Luisana, Maltese, Girolamo, Faiella, Eliodoro, Santucci, Domiziana, Pantano, Francesco, Vincenzi, Bruno, Tonini, Giuseppe, Papalia, Rocco, and Denaro, Vincenzo
- Subjects
- *
KIDNEY tumors , *ARTIFICIAL intelligence , *CLINICAL medicine research , *CANCER patient medical care , *BREAST tumors , *DESCRIPTIVE statistics , *PROSTATE tumors , *BONE metastasis , *SYSTEMATIC reviews , *MEDLINE , *NUCLEAR medicine , *MEDICAL databases , *LUNG tumors , *ONLINE information services , *MACHINE learning , *MOLECULAR biology , *SENSITIVITY & specificity (Statistics) - Abstract
Simple Summary: Bone metastases represent a serious and common challenge in advanced cancer patients, making early detection crucial. The growing implementation of artificial intelligence (AI) in various medical fields is revolutionizing healthcare by enhancing diagnostic accuracy. This systematic review includes 59 articles and sought to assess the potential of machine learning models in the fields of nuclear medicine, clinical research, radiology, and molecular biology. The review provides a comprehensive analysis of AI's effectiveness in detecting bone metastases, which had not yet been thoroughly conducted. The findings highlight the benefits of integrating AI technologies in the inspected fields, encouraging further advancements and adoption of AI to ultimately improve patient care and treatment planning. This study provides invaluable perceptions into the promising application of computational intelligence in the detection of bone metastases, demonstrating its superiority over standard tests. However, further research is necessary to substantiate these findings with the aim of developing better-trained data-driven models soon. Background: Metastasis commonly occur in the bone tissue. Artificial intelligence (AI) has become increasingly prevalent in the medical sector as support in decision-making, diagnosis, and treatment processes. The objective of this systematic review was to assess the reliability of AI systems in clinical, radiological, and pathological aspects of bone metastases. Methods: We included studies that evaluated the use of AI applications in patients affected by bone metastases. Two reviewers performed a digital search on 31 December 2023 on PubMed, Scopus, and Cochrane library and extracted authors, AI method, interest area, main modalities used, and main objectives from the included studies. Results: We included 59 studies that analyzed the contribution of computational intelligence in diagnosing or forecasting outcomes in patients with bone metastasis. Six studies were specific for spine metastasis. The study involved nuclear medicine (44.1%), clinical research (28.8%), radiology (20.4%), or molecular biology (6.8%). When a primary tumor was reported, prostate cancer was the most common, followed by lung, breast, and kidney. Conclusions: Appropriately trained AI models may be very useful in merging information to achieve an overall improved diagnostic accuracy and treatment for metastasis in the bone. Nevertheless, there are still concerns with the use of AI systems in medical settings. Ethical considerations and legal issues must be addressed to facilitate the safe and regulated adoption of AI technologies. The limitations of the study comprise a stronger emphasis on early detection rather than tumor management and prognosis as well as a high heterogeneity for type of tumor, AI technology and radiological techniques, pathology, or laboratory samples involved. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
45. Performance of Contrast-Enhanced Mammography (CEM) for Monitoring Neoadjuvant Chemotherapy Response among Different Breast Cancer Subtypes.
- Author
-
Vidali, Sofia, Irmici, Giovanni, Depretto, Catherine, Bellini, Chiara, Pugliese, Francesca, Incardona, Ludovica Anna, Di Naro, Federica, De Benedetto, Diego, Di Filippo, Giacomo, Ferraro, Fabiola, De Berardinis, Claudia, Miele, Vittorio, Scaperrotta, Gianfranco, and Nori Cucchiari, Jacopo
- Subjects
- *
HORMONES , *BREAST tumors , *POLYMERASE chain reaction , *TREATMENT effectiveness , *RETROSPECTIVE studies , *TERTIARY care , *CANCER patients , *DESCRIPTIVE statistics , *ADJUVANT chemotherapy , *IODINE compounds , *GENES , *COMBINED modality therapy , *MAMMOGRAMS , *ONCOGENES , *DRUG efficacy , *TUMOR classification , *CONTRAST media , *SENSITIVITY & specificity (Statistics) - Abstract
Simple Summary: The indications for neoadjuvant chemotherapy (NAT) have expanded in recent years both for locally advanced and early-stage breast cancer, with different pathological complete response (pCR) rates among different molecular subtypes. This retrospective two-center study aims to evaluate the diagnostic performance of Contrast-Enhanced Mammography (CEM) in assessing the response to NAT in breast cancer patients. The CEM sensitivity and specificity were 66.2% and 75.2%, with the highest specificity (80.9%) in HR+/HER2− and the highest sensitivity (70%) in triple-negative breast cancer. CEM is a valid tool to assess the pCR with different performances among the molecular subtypes and may be reliable in the decisional process of de-escalating surgical management. Neoadjuvant chemotherapy (NAT) plays a crucial role in breast cancer (BC) treatment, both in advanced BC and in early-stage BC, with different rates of pathological complete response (pCR) among the different BC molecular subtypes. Imaging monitoring is mandatory to evaluate the NAT efficacy. This study evaluates the diagnostic performance of Contrast-Enhanced Mammography (CEM) in BC patients undergoing NAT. This retrospective two-center study included 174 patients. The breast lesions were classified based on the molecular subtypes in hormone receptor (HR+)/HER2−, HER2+, and triple-negative breast cancer (TNBC). The histopathological analysis performed following surgery was used as a reference standard for the pCR. Sensitivity, specificity, PPV, and NPV were measured overall and for the different subtypes. We enrolled 174 patients, 79/174 (46%) HR+/HER2−, 59/174 (33.9%) HER2+, and 35/174 (20.1%) TNBC; the pCR was found in 64/174 (36.8%), of which 57.1% were TNBCs. In the total population, the CEM sensitivity and specificity were 66.2% and 75.2%, with a PPV of 61.4% and an NPV of 78.8%. The highest specificity (80.9%) and NPV (91.7%) were found in HR+/HER2−, while the highest sensitivity (70%) and PPV appeared (73.7%) in TNBC. The results indicate that CEM is a valid tool to assess the pCR, with different performances among the subtypes of BC. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
46. Understanding the Role of Toll-Like Receptors 9 in Breast Cancer.
- Author
-
Al-alem, Umaima, Al-Saruri, Alaa, Bamahros, Hasan, Mahmoud, Abeer M., Sible, Emily, and Hasan, Uzma A.
- Subjects
- *
VITAMIN D deficiency , *HEALTH literacy , *TOBACCO , *BREAST tumors , *EPIGENOMICS , *SEDENTARY lifestyles , *TOLL-like receptors , *OXIDATIVE stress , *DESCRIPTIVE statistics , *GENE expression , *SYSTEMATIC reviews , *MEDLINE , *MESSENGER RNA , *WORLD health , *ONLINE information services , *INFLAMMATION , *NATURAL immunity , *GENETICS , *OBESITY - Abstract
Simple Summary: Breast cancer is a major global issue, ranking as the second most common cancer among women. Various factors such as genetics, epigenetics, obesity, sedentary lifestyle, tobacco use, and vitamin D deficiency have been implicated in its prevalence. Toll-like receptor 9 (TLR9) has emerged as a potential key factor, yet its role in breast cancer has not been fully explored. TLR9, a component of the innate immune system, recognizes unmethylated CpG motifs, thus initiating immune responses. Understanding TLR9 expression and function in breast tissue, particularly in distinguishing between normal and cancerous tissue, is crucial. This review examines the existing literature on TLR9 expression in both normal and cancerous breast tissue, aiming to identify knowledge gaps and enhance our understanding of TLR9's role in breast cancer. The ultimate goal is to enhance our understanding of TLR9's involvement in breast cancer pathogenesis, which could potentially lead to novel diagnostic markers or therapeutic targets, thereby improving patient outcomes and advancing breast cancer treatment strategies. Breast cancer is a significant global issue, ranking as the second most common cancer among women worldwide and a leading cause of cancer-related deaths. Although the exact causes of this increase remain unclear, factors such as genetics, epigenetics, obesity, sedentary lifestyle, tobacco use, and vitamin D deficiency have been implicated. The Toll-like receptor 9 (TLR9) is recognized for its role in inflammation and innate immunity; however, its specific involvement in breast cancer pathogenesis requires further investigation. This study aims to systematically review the existing literature on TLR9 expression in normal and cancerous breast tissue, providing current knowledge and identifying gaps. Relevant articles in English were from PubMed, Scopus, and Google Scholar, with the inclusion criteria focusing on studies evaluating TLR9 mRNA and protein expression. The review found that TLR9 mRNA and protein exhibit variable expressions in both normal and cancerous breast tissue, highlighting the need for further research to clarify TLR9's role in breast cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
47. Omission of Completion Axillary Lymph Node Dissection for Patients with Breast Cancer Treated by Upfront Mastectomy and Sentinel Node Isolated Tumor Cells or Micrometastases.
- Author
-
Houvenaeghel, Gilles, Heinemann, Mellie, Classe, Jean-Marc, Bouteille, Catherine, Gimbergues, Pierre, Azuar, Anne-Sophie, Martino, Marc, Tallet, Agnès, Cohen, Monique, and de Nonneville, Alexandre
- Subjects
- *
BREAST cancer prognosis , *BREAST tumors , *MICROMETASTASIS , *AXILLARY lymph node dissection , *DESCRIPTIVE statistics , *MULTIVARIATE analysis , *LONGITUDINAL method , *MASTECTOMY , *PROGRESSION-free survival , *OVERALL survival - Abstract
Simple Summary: Omission of completion axillary lymph node dissection (cALND) in patients undergoing mastectomy with sentinel node (SN) isolated tumor cells (ITC) or micrometastases is discussed. We evaluated the impact of cALND omission on survival in breast cancer (BC) patients treated by mastectomy with SN ITC or micrometastases. Among 554 BC, the non-SN involvement rate was 13.2%. With a median follow-up of 66.46 months, multivariate analysis showed that cALND omission was significantly associated with overall survival (OS, HR: 2.583, p = 0.043), disease-free survival (DFS, HR: 2.538, p = 0.008), and metastasis-free survival (MFS, HR: 2.756, p = 0.014). For Her2-positive or triple-negative patients, DFS was significantly impacted by cALND omission (HR: 38.451, p = 0.030). In ER-positive Her2-negative patients, DFS, OS, RFS, and MFS were also significantly affected (HR: 2.358, 3.317, 2.538, 2.756). For 161 patients ≤ 50 years with ER-positive/Her2-negative BC, OS and BCSS were notably associated with cALND omission (HR: 103.47 and 50.874). These findings suggest a negative prognostic impact of cALND omission in patients with SN micrometastases or ITC. Omission of completion axillary lymph node dissection (cALND) in patients undergoing mastectomy with sentinel node (SN) isolated tumor cells (ITC) or micrometastases is debated due to potential under-treatment, with non-sentinel node (NSN) involvement detected in 7% to 18% of patients. This study evaluated the survival impact of cALND omission in a cohort of breast cancer (BC) patients treated by mastectomy with SN ITC or micrometastases. Among 554 early BC patients (391 pN1mi, 163 ITC), the NSN involvement rate was 13.2% (49/371). With a median follow-up of 66.46 months, multivariate analysis revealed significant associations between cALND omission and overall survival (OS, HR: 2.583, p = 0.043), disease-free survival (DFS, HR: 2.538, p = 0.008), and metastasis-free survival (MFS, HR: 2.756, p = 0.014). For Her2-positive or triple-negative patients, DFS was significantly affected by cALND omission (HR: 38.451, p = 0.030). In ER-positive Her2-negative BC, DFS, OS, recurrence-free survival (RFS), and MFS were significantly associated with cALND omission (DFS HR: 2.358, p = 0.043; OS HR: 3.317; RFS HR: 2.538; MFS HR: 2.756). For 161 patients aged ≤50 years with ER-positive/Her2-negative cancer, OS and breast cancer-specific survival (BCSS) were notably impacted by cALND omission (OS HR: 103.47, p = 0.004; BCSS HR: 50.874, p = 0.035). These findings suggest a potential negative prognostic impact of cALND omission in patients with SN micrometastases or ITC. Further randomized trials are needed. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
48. The Engineered Drug 3′UTRMYC1-18 Degrades the c-MYC-STAT5A/B-PD-L1 Complex In Vivo to Inhibit Metastatic Triple-Negative Breast Cancer.
- Author
-
Awah, Chidiebere U., Mun, Joo Sun, Paragodaarachchi, Aloka, Boylu, Baris, Ochu, Chika, Matsui, Hiroshi, and Ogunwobi, Olorunseun O.
- Subjects
- *
BREAST cancer prognosis , *THERAPEUTIC use of antineoplastic agents , *RESEARCH funding , *CANCER invasiveness , *BREAST tumors , *TRANSCRIPTION factors , *TREATMENT effectiveness , *IN vivo studies , *METASTASIS , *MESSENGER RNA , *NUCLEOTIDES , *MICE , *ANIMAL experimentation , *DRUG development , *SURVIVAL analysis (Biometry) , *DRUG tolerance , *SEQUENCE analysis , *DISEASE progression - Abstract
Simple Summary: The overexpression of c-MYC is implicated in many cancers, and it drives the tumors' aggressiveness and metastatic progression, but there is no clinically approved drug that targets MYC. We discovered that the MYC mRNA is stabilized by the poly U sequences on its 3′UTR. We engineered these stable elements into unstable forms in a way such that they degraded the target MYC mRNA through a process called nonsense-mediated decay. We developed the drug 3′UTRMYC1-18 and evaluated its therapeutic efficacy in a metastatic model of c-MYC-driven TNBC in vivo by delivering it with iron oxide nanocages. The constructs inhibited primary and metastatic lung and liver cancers by degrading the c-MYC-STAT5A/5B-PD-L1 complex and achieved significant survival outcomes. The in vivo data strongly suggests that this new drug is therapeutically effective in inhibiting c-MYC-driven triple-negative breast cancer and metastatic tumors. The drug was well tolerated and represents a new arsenal to target the deadly TNBC and will offer hope to patients who need it. c-MYC is overexpressed in 70% of human cancers, including triple-negative breast cancer (TNBC), yet there is no clinically approved drug that directly targets it. Here, we engineered the mRNA-stabilizing poly U sequences within the 3′UTR of c-MYC to specifically destabilize and promote the degradation of c-MYC transcripts. Interestingly, the engineered derivative outcompetes the endogenous overexpressed c-MYC mRNA, leading to reduced c-MYC mRNA and protein levels. The iron oxide nanocages (IO-nanocages) complexed with MYC-destabilizing constructs inhibited primary and metastatic tumors in mice bearing TNBC and significantly prolonged survival by degrading the c-MYC-STAT5A/B-PD-L1 complexes that drive c-MYC-positive TNBC. Taken together, we have described a novel therapy for c-MYC-driven TNBC and uncovered c-MYC-STAT5A/B-PD-L1 interaction as the target. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
49. Radiosynthesis and Preclinical Evaluation of 18 F-Labeled Estradiol Derivatives with Different Lipophilicity for PET Imaging of Breast Cancer.
- Author
-
Friedel, Anna, Prante, Olaf, and Maschauer, Simone
- Subjects
- *
BREAST tumor diagnosis , *CLINICAL drug trials , *BIOLOGICAL models , *IN vitro studies , *RADIOPHARMACEUTICALS , *RESEARCH funding , *BREAST tumors , *ANTINEOPLASTIC agents , *POSITRON emission tomography , *TREATMENT effectiveness , *IN vivo studies , *CANCER cell culture , *RADIOISOTOPES , *DESCRIPTIVE statistics , *ESTRADIOL , *MICE , *CELL lines , *ANIMAL experimentation , *MOLECULAR structure , *FLUORINE isotopes , *DRUG development , *COMPARATIVE studies , *PHARMACODYNAMICS - Abstract
Simple Summary: Breast cancer is one of the most prevalent forms of cancer diagnosed in women worldwide. Since the estradiol receptor (ER) is overexpressed in 75% of breast tumors, it is a reasonable target for tumor diagnosis and therapy. This study focuses on the development and preclinical evaluation of readily synthesized 18F-labeled estradiol derivatives with different lipophilicity. The least hydrophilic derivative, 18F-TA-Glyco-EE, showed the highest cellular uptake in ER-positive breast cancer cells. The in vivo PET imaging of breast tumor-bearing mice demonstrated the desired rapid clearance of the tracer from the excretory organ through the liver. The in vitro autoradiography of ER-positive tumor sections confirmed the high specific binding of 18F-TA-Glyco-EE. In conclusion, 18F-TA-Glyco-EE may be a promising candidate for imaging of ER-positive breast cancer. About 75% of breast tumors show an overexpression of the estradiol receptor (ER), making it a valuable target for tumor diagnosis and therapy. To date, 16α-[18F]fluoroestradiol (FES) is the only FDA-approved imaging probe for the positron emission tomography (PET) imaging of ER-positive (ER+) breast cancer. However, FES has the drawback of a high retention in the liver. Therefore, the aim of this study was the development and preclinical evaluation of estradiol (E2) derivatives with different lipophilicity. Three 18F-labeled prosthetic groups (two glycosyl and one PEG azide) were chosen for conjugation with ethinyl estradiol (EE) by 18F-CuAAC (Cu-catalyzed azide-alkyne cycloaddition). The cellular uptake in ER+ MCF-7 tumor cells was highest for the less hydrophilic derivative (18F-TA-Glyco-EE). In nude mice bearing different breast tumors (ER+ MCF-7 and T47D versus ER− MDA-MB-231), 18F-TA-Glyco-EE revealed a high uptake in the liver (13%ID/g, 30 min p.i.), which decreased over 90 min to 1.2%ID/g, indicating fast hepatobiliary clearance. The statistically significant difference of 18F-TA-Glyco-EE uptake in T47D compared to MDA-MB-231 tumors at 60–90 min p.i. indicated ER-specific uptake, whereas in vivo PET imaging did not provide evidence for specific uptake of 18F-TA-Glyco-EE in MCF-7 tumors, probably due to ER occupation by E2 after E2-dependent MCF-7 tumor growth in mice. However, in vitro autoradiography revealed a high specific binding of 18F-TA-Glyco-EE to ER+ tumor slices. We conclude that 18F-TA-Glyco-EE, with its increased hydrophilicity after deacetylation in the blood and thus rapid washout from non-target tissues, may be a viable alternative to FES for the PET imaging of breast cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
50. Depicting Biomarkers for HER2-Inhibitor Resistance: Implication for Therapy in HER2-Positive Breast Cancer.
- Author
-
Cai, Alvan, Chen, Yuan, Wang, Lily S., Cusick, John K., and Shi, Yihui
- Subjects
- *
BREAST cancer prognosis , *THERAPEUTIC use of antineoplastic agents , *THERAPEUTIC use of monoclonal antibodies , *DRUG resistance in cancer cells , *BREAST tumors , *PROTEIN-tyrosine kinase inhibitors , *TUMOR markers , *EPIDERMAL growth factor , *DRUG approval , *MOLECULAR structure , *PROGRESSION-free survival , *OVERALL survival , *DISEASE progression - Abstract
Simple Summary: The development of HER2-inhibitors for the treatment of HER2-positive breast cancer represented a breakthrough in targeted tumor therapy. However, as for other targeted therapeutics, drug resistance remains a serious challenge to the treatment of HER2+ BC. Recent research has identified critical biomarkers for HER2-inhibitor resistance and explored more effective treatment regimens in HER2+ breast cancer to overcome drug resistance; however, research on several potential biomarkers and promising alternative therapies remains incomplete. HER2 (human epidermal growth factor receptor 2) is highly expressed in a variety of cancers, including breast, lung, gastric, and pancreatic cancers. Its amplification is linked to poor clinical outcomes. At the genetic level, HER2 is encoded by the ERBB2 gene (v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2), which is frequently mutated or amplified in cancers, thus spurring extensive research into HER2 modulation and inhibition as viable anti-cancer strategies. An impressive body of FDA-approved drugs, including anti-HER2 monoclonal antibodies (mAbs), antibody–drug conjugates (ADCs), and HER2-tyrosine kinase inhibitors (TKIs), have demonstrated success in enhancing overall survival (OS) and disease progression-free survival (PFS). Yet, drug resistance remains a persistent challenge and raises the risks of metastatic potential and tumor relapse. Research into alternative therapeutic options for HER2+ breast cancer therefore proves critical for adapting to this ever-evolving landscape. This review highlights current HER2-targeted therapies, discusses predictive biomarkers for drug resistance, and introduces promising emergent therapies—especially combination therapies—that are aimed at overcoming drug resistance in the context of HER2+ breast cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.